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 Multicomponent reactions (MCRs) are processes in which three or more reactants 
are combined in one pot to form products that display structural features from each 
reactant. For this reason, MCRs provide rapid access to chemically diverse structures in 
an operationally simple manner. MCRs that produce drug-like structures are particularly 
useful in pharmaceutical development.  
 As part of our ongoing effort to improve and expand synthetically useful MCRs, 
tert-butylisonitrile was developed as an inexpensive, efficient, and readily available 
“convertible isonitrile”, one whose post-condensation product (typically a carboxamide) 
can be converted to a variety of new functionalities. The process, which occurred under 
mild nonaqueous conditions, left carboxylic esters unaffected and transformed MCR 
amides into useful carboxylic acids for further synthetic elaboration. We further showed 
that n-butylisonitrile may provide a viable alternative to other convertible isonitriles for 
amide-to-ester transformations in Ugi reactions. 
 In another project, a simple and general synthesis of carbonimidic dichlorides 
from isonitriles was developed using sulfuryl choride at low temperature. Carbonimidic 
dihalides are found in several natural products and have been used as protecting groups 
for isonitriles. The method, which suppressed free radical chlorination, rapidly and 
  
selectively furnished the corresponding carbonimidic dichlorides in excellent yields 
without further purification.  
Published reports on the reaction of nitronates with thiols under strongly basic 
conditions to form thiohydroximate esters led to an investigation on the analogous 
reaction of nitronates with amines to afford the corresponding amidoximes, an important 
family of medicinally active compounds. During this investigation, the first example of 
an amidoxime-to-amidine transformation by nucleophilic addition of an amine and 
elimination of NH2OH was discovered. The effect of metallating agent and amine 
substitution was also studied. Two generally useful sets of conditions were developed and 
applied to the preparation of a representative family of amidoximes. 
This thesis also describes attempts to replace the intermediate iminium 
electrophile in the Ugi reaction with a thionium electrophile. In the course of that study, a 
rapid and gentle catalytic oxidation of isonitriles to isocyanates was serendipitously 
discovered. The new method proved to be simple and easy to use. It generated only 
volatile and innocuous byproducts, and represented a very mild, rapid, and 
environmentally acceptable procedure for preparing isocyanates from isonitriles. 
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Introduction 
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1.1 Background 
 Multicomponent reactions (MCRs) are chemical reactions in which three or more 
starting materials combine to form a product.
1
 Most or all of the atoms from the reactants 
contribute to the newly formed product. The structure of the final product is often very 
complex as it displays the features of each input. Many MCRs produce heterocyclic rings 
and/or drug-like structures that are often present in pharmaceutical agents. MCRs are 
ideal tools for building large collections of structurally diverse compounds. Many 
bioactive compounds and pharmaceutical drugs have been discovered by combinatorial 
chemistry through screening such collections.
2
 
Used primarily by pharmaceutical companies, combinatorial chemistry describes 
a number of laboratory techniques that make it possible to synthesize large collections of 
related compounds in a single process.
3
 This process is often carried out in a 
preprogramed and computer-controlled sequence. Combinatorial chemistry uses either 
solid-phase synthesis or solution-phase synthesis to generate these chemical libraries. 
Solid-phase synthesis uses resin beads as a means to bind the chemicals before doing the 
chemistry. The products are purified by washing away excess reagents and by-products 
after each reaction step.  
Two commonly used techniques in solid-phase synthesis are mix-and-split 
synthesis and parallel synthesis. The mix-and-split technique was first used by Merrifield 
in 1963 to synthesize a library of peptides.
4
 A sample of resin beads was split equally into 
portions. Each portion was then coupled with a different starting amino acid. The amino 
acid-bound beads were mixed thoroughly and then split again into portions. Each new 
portion was then reacted with a second set of amino acids to give a complete set of 
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possible outcomes of dimers. The cycle of mixing and splitting was repeated with more 
sets of amino acids to generate a library of peptides. The mix-and-split technique can also 
be used to synthesize libraries of other organic compounds. The parallel synthesis 
technique was developed by Geysen et al. in 1984 to synthesize an array of peptides 
using plastic rods that were coated with the solid support.
5
 By immersing the rods into the 
solutions of different amino acids in a stepwise process, they were able to synthesize an 
array of 96 different peptides.  
While solid-phase synthesis is very easy to conduct, it can generally only produce 
small quantities of products.
6,7
 The adaptation of the reaction conditions that are normally 
used in solution synthesis for solid-phase synthesis also takes time. Solution-phase 
synthesis can produce a much larger chemical library than solid-phase synthesis, making 
it the method of choice for many chemists. Solution-phase synthesis can also use a 
broader range of reactions; thus, it can produce a much more diverse chemical library.  
Although combinatorial chemistry uses a variety of laboratory techniques to 
generate large chemical libraries, the synthetic approach still involves conventionally 
linear processes. To shorten the time and improve the efficiency in creating libraries of 
complex structures, combinatorial chemists have been using MCRs in both solid-phase 
synthesis and solution-phase synthesis.
8
 Multicomponent reactions represent an obvious 
advantage over conventional synthetic approaches in generating these large chemical 
libraries. By combining many inputs and forming several new bonds in a one-pot 
procedure, a MCR provides rapid access to chemically diverse structures in an 
operationally simple manner. New distinct molecules are produced by simply changing 
any one of the inputs.
6
 Moreover, MCRs often occur with high atom economy, which 
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increases both synthetic efficiency (by reducing time, labor, cost, and chemical waste 
generation) and molecular complexity. As synthetic chemists pay increasing attention to 
efficient and environmentally benign routes of synthesis, the use of MCRs has grown 
more attractive in creating large chemical libraries.  
Figure 1.1 depicts some of the most well-known examples of MCRs. In 1850, 
Strecker reported the synthesis of amino acids through the condensation of aldehydes, 
ammonia, and hydrogen cyanide, which has been widely recognized as the first MCR.
9
  
In 1912, Mannich reported that the reaction of non-enolizable aldehydes, amines, and 
enolizable ketones produced aminocarbonyls.
10
 The first MCR involving an isonitrile was 
reported by Passerini in 1921, taking advantage of the unique divalent nature of the 
isonitrile carbon.
11
 In the Passerini reaction, α-acyloxyamides were formed through the 
condensation of carbonyl compounds, carboxylic acids, and isonitriles. In 1959, Ugi 
reported that the reaction of carbonyl compounds, amines, carboxylic acids, and 
isonitriles generated α-aminoacyl amides.12 In 1882, Hantzsch reported that an aldehyde, 
2 equivalents of a β-ketoester, and ammonia combined to give a dihydropyridine 
derivative.
13
 A subsequent oxidation would lead to a corresponding pyridine. In 1890, 
Hantzsch reported the synthesis of substituted pyrroles through the condensation of 
primary amines, β-ketoesters, and α-haloketones.14 In 1891, Biginelli reported that the 
reaction of aldehydes, ureas, and β-ketoesters generated 3,4-dihydropyrimidin-2(1H)-
ones.
15
 Reported by Bergs in 1929 and improved by Bucherer in 1934, the Bucherer-
Bergs reaction is the condensation of aldehydes or ketones with potassium cyanide  and 
ammonium carbonate to give hydantoins.
16,17
 Of particular interest, the Hantzsch 
dihydropyridine synthesis, the Hantzsch pyrrole synthesis, the Biginelli reaction, and the 
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Bucherer-Bergs reaction produced heterocyclic compounds that are often featured in 
pharmaceutical products. 
 
Figure 1.1 Examples of Some Well-Known MCRs. 
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 Because many MCRs produce heterocyclic rings and/or drug-like structures, 
MCRs have also been used in the synthesis of many drugs. For example, the Hantzsch 
dihydropyridine synthesis has been used to synthesize many different substituted 1,4-
dihydropyridines (1,4-DHPs), which are well known in pharmacology as L-type calcium 
channel blockers.
18
 Many 1,4-DHPs, such as amlodipine, felodipine, nicardipine, and 
nifedipine, have been used in treatment of angina and hypertension (Figure 1.2). Recent 
generations of 1,4-DHPs display antianginal, anticancer, antidiabetic, bronchodilating, 
neurotropic, and other pharmacological activities. 
 
 
Figure 1.2 Some Well-Known Drugs in the 1,4-DHP Family.
18
 
  
Amlodipine 5, for example, was recently produced using the Hantzsch 
dihydropyridine synthesis in a U.S. patent (Scheme 1.1).
19
 The Hantzsch dihydropyridine 
product 4 was formed by the condensation of 2-chlorobenzaldehyde 1, methyl (E)-3-
aminocrotonate 2, and ethyl-3-oxidanylidene-4-(2-pyrrol-1-ylethoxy)butanoate 3. 
Subsequent removal of the amine protective group afforded amlodipine 5 in 90% overall 
yield. 
7 
 
 
Scheme 1.1
19
 
  
The Biginelli reaction has been used to synthesize many different substituted 3,4-
dihydropyrimidinones (3,4-DHPMs), which are well-known in pharmacology as calcium 
channel blockers and have shown antiviral, antiinflammatory, antibacterial, 
anticarcinogenic, antihypertensive, and antagonist activities.
20
 A typical 3,4-DHPM 6 
might be constructed from the condensation of an aryl aldehyde 7, a β-ketoester 8, and a 
urea or thiourea 9 (Figure 1.3).
20–23
 Examples of 3,4-DHPMs include SQ 32547 and 
SWO2, which have been discovered as potent antihypertensive agents, and monastrol, 
which is known as the only mitotic kinesin Eg5 inhibitor (Figure 1.4).
23
 Mitotic kinesin 
Eg5 is a motor protein that plays an essential role in cell division. Monastrol is currently 
under investigation for its anticancer activity.  
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Figure 1.3 The Biginelli Synthesis of a Typical 3,4-DHPM 6.
20–23
 
 
 
Figure 1.4 Some Well-Known Drugs in the 3,4-DHPM Family.
23
 
 
Since its discovery, the Passerini reaction has been widely used in the synthesis of 
many drugs and bioactive compounds. For example, Schmidt and Weinbrenner used a 
Passerini reaction as the first step in their synthesis of eurystatin A (Scheme 1.2).
24
 
Eurystatin A has been reported to inhibit the activity of prolyl endopeptidase (PEP). The 
Passerini product 13 was formed by the condensation of aldehyde 10, benzoic acid 11, 
and isonitrile 12. Subsequent modification afforded eurystatin A. 
9 
 
Scheme 1.2
24
 
  
Kalinski et al. recently used a 2-component Passerini to synthesize bicalutamide 
14 (Figure 1.5).
25
 Bicalutamide is an oral anti-androgen drug that is used in the treatment 
of prostate cancer and hirsutism.
26,27
 Peak sales for bicalutamide (2006) were $1.5 
billion.
28
 Bicalutamide 14 was constructed by the combination of the aldehyde 15 and the 
isonitrile 16 using a Lewis acid as a promoter.  
 
 
Figure 1.5 A 2-Component Passerini Synthesis of Bicalutamide. 
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Similar to the Passerini reaction, the Ugi reaction has also been widely used in the 
synthesis of many drugs and bioactive compounds since its discovery. For example, 
Kalinski et al. used a 3-component Ugi reaction to synthesize clopidogrel 23 (Scheme 
1.3).
25
 Clopidogrel is an oral antiplatelet agent that is used to inhibit blood clots in many 
diseases. In 2005, clopidogrel was the world’s second-highest-selling drug. The Ugi 
product 21 was formed by the condensation of 2-chlorobenzaldehyde 17, 4,5,6,7-
tetrahydrothieno[3,2-c]pyridine 18, 1-isocyanocyclohexene (Armstrong isonitrile) 19, 
and formic acid 20. Subsequent hydrolysis of the amide in 21 and esterification of 
carboxylic acid 22 afforded clopidogrel 23 in high yield.  
 
 
Scheme 1.3
25
 
 
 The Ugi reaction was recently used by Fukuyama et al. as the first step in the 
synthesis of trabectedin, also known as ecteinascidin 743 or ET-743 (Scheme 1.4).
29
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Trabectedin is a very potent antitumor agent that is used in treatment of soft tissue 
sarcoma and ovarian cancer.
30,31
 It is also in phase II trials for treating breast cancer and 
paediatric tumors.
32
 The Ugi product 28 was formed by the condensation of acetaldehyde 
24, the amine 25, carboxylic acid 26, and p-methoxyphenyl isonitrile 27. Subsequent 
modification afforded trabectedin 29. 
 
 
Scheme 1.4
29
 
 
1.2 Improving Known MCRs and Evolving New MCRs 
MCRs offer rapid access to chemically diverse structures that have heterocyclic 
rings and/or drug-like features. For these and other reasons, the use of MCRs in the 
discovery process of new drugs and bioactive compounds has intensified lately.
33
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Numerous research groups are now focusing on MCR design and development, and 
important advances in MCRs have been discovered either by chance or by design. 
One example of the discovery of new MCRs by chance is illustrated by the work 
of Lacke and Webber.
34
 After selecting 10 starting materials with different functional 
groups, the compounds were mixed in all possible combinations of 2 to 10 components. 
Overall, 1013 reactions were carried out using an automated robotic system. HPLC-MS 
was employed to identify new peaks that were different from the reactants. Ultimately, 
the team “rediscovered” the Ugi reaction and also identified a new MCR that furnished 
2,3-dihydrocinnoline 34 by the condensation of benzylisonitrile 30, cyclohexanone 31, 
and 4-methoxyphenyl hydrazine 32 (Scheme 1.5).  
 
 
Scheme 1.5
33
 
 
One example of the discovery of new MCRs by design is the union of two or 
more known MCRs. This concept was first described by Dömling and Ugi in 1993.
35
 
They also reported the first seven-component reaction by combining the Asinger reaction 
and the Ugi reaction (Scheme 1.6). The intermediate 39 of the Asinger four-component 
13 
 
reaction was formed by the condensation of sodium hydrosulfide 35, 1-bromo-2,2-
dimethylacetaldehyde 36, ammonia 37, and isobutyric aldehyde 38. This intermediate 39 
contained a Schiff base, which was the starting point for a subsequent Ugi reaction with 
tert-butylisonitrile 40 and methoxycarboxylic acid 41. Methoxycarboxylic acid 41 was 
thus generated from methanol 42 and carbon dioxide 43. The final product of this seven-
component reaction was thiazolidine 44. 
 
 
Scheme 1.6
7,35
 
 
Our laboratory has been applying logical strategies to improve known MCRs and 
evolve new MCRs.
36
 In order to be a useful lead compound for pharmaceutical 
development, a MCR product needs to possess a drug-like (i.e., natural product-like) 
structure. Because there are only a handful of MCRs that satisfy this criterion, most 
MCRs are not useful in drug discovery. The strategies that drive our research goals have 
aimed to find practical and useful MCRs for drug discovery. 
14 
 
One approach to improve known MCRs takes advantage of detailed knowledge of 
the MCR reaction mechanisms, and applies retrosynthetic analysis to the intermediates in 
a logic-based approach. Once a new independent route to an intermediate is identified, it 
is carefully evaluated against our goal. Such a finding would constitute a new route to the 
final product through new starting materials and reactions. As one illustration of MCR 
improvement, Figure 1.6 depicts a typical four-component reaction that combines the 
inputs A, B, C, and D, each representing a family of compounds. Assuming the overall 
transformation proceeds via symbolic intermediates [A, D] and [A, D, C], which are 
depicted as the blue line and blue triangle, respectively, one may then apply 
retrosynthetic analysis to the intermediate [A, D], for example, and identify an 
independent route to the intermediate [A, D] from Q + R + S. Such a finding would thus 
constitute a new five-component route to the final product [A, B, C, D] by combining Q 
+ R + S with B and C. Besides producing the final product from a more diverse set of 
reactants, this new five-component route also would enhance the dimensionality of the 
reaction and broaden the potential size of chemical libraries. For example, Simoneau 
pointed out that a four-component reaction with 10 inputs each would theoretically 
produce a chemical library of 10,000 compounds, while a five-component reaction with 
10 inputs each would theoretically produce a chemical library of 100,000 compounds.
6
 
The diversity of the chemical libraries would also increase as they incorporate structural 
diversity from five, instead of four, reactants.  
15 
 
 
Figure 1.6 Improving Known MCRs by Retrosynthetic Analysis.
36 
 
To evolve new MCRs, our group has developed a logic-based approach called the 
single reactant replacement (SRR) approach.
36
 In this approach, careful analysis of the 
reaction mechanism is conducted to identify the key reactivity element (KRE) of each 
reactant in a known MCR. For example, a reactant might serve as an electrophile, or 
base, or chelating agent, or hydrogen bond donor, just to name a few possible KREs.  
Once the KRE has been identified, the chemist might replace one reactant with another 
input having the same KRE. This new input could carry an additional orthogonal 
reactivity element that might ultimately direct the reaction, either during or after, to a 
different outcome. As one illustration of this approach, Figure 1.7 depicts a three-
component reaction that combines the inputs A, B, and C, each representing a family of 
compounds. If one replaces A with a different input W that shares the same KRE with A, 
one might direct the reaction to the formation of a new chemical structure that is different 
from the product of the parent MCR. The SRR approach is iterative and can then be 
reapplied to one of the other inputs to evolve the reaction to a second generation and so 
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on. Ideally, the difference in the structures of the final products would increase after each 
iteration. Gradually, a new MCR would be evolved and would be distinct from its 
predecessors. The SRR approach would thus further expand the repertoire of MCRs in 
building chemical libraries. 
 
 
Figure 1.7 Developing New MCRs by the Single Reactant Replacement Approach.
36
 
 
 An early example of the SRR approach can be seen in the development by Ivar 
Ugi of a new MCR based on the Passerini reaction, where the functional similarities  
between simple carbonyl compounds and their corresponding imines were exploited by 
Ugi. As shown in Figure 1.1, in the Passerini reaction, an α-acyloxyamide was formed 
through the condensation of either an aldehyde or a ketone, a carboxylic acid, and an 
isonitrile.
11
 The accepted mechanism for the Passerini reaction is depicted in Scheme 1.7. 
The carbonyl 45 is activated by the carboxylic acid 46 via hydrogen bonding. 
Nucleophilic addition of the isonitrile 47 to the activated carbonyl affords the nitrilium 
ion 48. A second nucleophilic addition of the carboxylate anion 49 to this intermediate 
17 
 
leads to the alcohol 50. The final step is a Mumm rearrangement, which transfers the R3 
acyl group to the alcohol oxygen, affording the final product 51. 
 
 
Scheme 1.7 
  
 After careful analysis of the Passerini reaction mechanism and the functional roles 
of each reactant, Ugi recognized that an imine might play a role similar to the carbonyl in 
the Passerini reaction. In a 1962 article that reported his research on the α-addition of 
immonium ions and anions to isonitriles, Ugi noted that: “Had Passerini been conversant 
with present day views on reaction mechanisms while studying the reaction which now 
bears his name, he would probably have added ammonia or the primary amines, to his 
three starting materials and thereby discovered the α-amino alkylation of isonitriles and 
acids.”37 Effectively, Ugi was practicing the SRR approach when he replaced the 
carbonyl component 45 in the Passerini with a comparable electrophilic imine 52 
(Scheme 1.8). The α-aminoacyl amide product 53 would be formed through the 
condensation of the imine 52 with a carboxylic acid 46 and an isonitrile 47 in a similar 
mechanistic pathway.  
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Scheme 1.8 
 
 Following in Ugi’s footsteps and guided by the SRR approach, our laboratory has 
evolved several MCRs. In one example, the carboxylic acid component of the Passerini 
reaction was replaced with a Lewis acid such as TMSOTf.
38
 The resulting silylation of 
the carbonyl component (benzaldehyde) in the presence of isonitrile 56 led to α-
hydroxyamide 57 in good yield after aqueous workup (Scheme 1.9). In another variant, 
isonitriles that contain good donor groups, such as ethyl isocyanoacetate 59 or 2-
morpholinoethyl isonitrile 60 afforded ethoxyoxazoles or morpholinooxazoles 61 via 
neighboring group participation. The iterative aspect of the SRR approach was 
investigated by subsequently replacing the aldehydes 58 in the oxazole-forming reaction 
with the corresponding “iminium” species, which were made by premixing 58 with either 
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morpholine or dimethylamine 62. Bis-aminooxazoles 65 were obtained in good yields 
without the need for Lewis acid promoters. These reactions could be useful in finding 
drug lead compounds as many medicinally significant natural products bear substituted 
oxazole motifs.
39,40
 
 
 
Scheme 1.9
38
 
 Guided by the SRR approach, Oaksmith et al. in our group replaced the carbonyl 
component in the Passerini with an acylnitrile to test the effect of embedding an 
orthogonal reactivity element within the carbonyl component.
41
 The α-acyloxy-α-
cyanoamide 69 was formed in good yield by the condensation of an acylnitrile 66, a 
carboxylic acid 67, and an isonitrile 68 (Scheme 1.10). The α-acyloxy-α-cyanoamide 69 
was then directed to a different outcome by a simple catalytic hydrogenation. The 
nucleophilic amine group released in 71 triggered a rearrangement that produced β-amino 
acid diamide 72 as the final product. This two-stage process could be performed in one 
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pot without isolating the α-acyloxy-α-cyanoamide 69. Interestingly, the β-amino acid 
diamide or β-peptide motif is found in many medicinally significant natural products.42,43 
 Through post-condensation modification, our group was also successful in 
directing the α-acyloxy-α-cyanoamide 69 to 1,3-oxazoles or tetrazoles.44 This production 
was achieved by reacting 69 with diazomalonic esters or alkyl azides.  
 
 
Scheme 1.10
41
 
 
 Through careful analysis on the Ugi reaction mechanism and the functional roles 
of each reactant in the overall process, Simoneau et al. applied retrosynthetic analysis to 
the imine species 73 and identified an alternative route to the imine, leading to the 
development of a new 5-component Ugi reaction (Scheme 1.11).
45
 The key step in this 
process involves addition of organometallic reagents to nitriles. Simoneau et al. 
demonstrated that N-substituted imines 75 could be formed by the condensation of N-
unsubstituted ketimines 74 and primary amines R3NH2. This new finding led to a 
successful development of a new 5-component Ugi reaction. 
21 
 
 
Scheme 1.11
36
 
 
 As mentioned earlier, increasing the dimensionality of MCRs increases the 
potential size of the chemical library exponentially. Since there are only a few MCRs that 
are currently useful in drug discovery, our group wondered if a useful 2-component 
reaction could be transformed into a MCR. Appropriate 2-component reactions for this 
approach must not be elementary reactions; i.e. they must involve at least one 
intermediate that could be subjected to retrosynthetic analysis. The well-known Fischer 
indole reaction served as a good case in point (Scheme 1.12).
46
 In the Fischer indole 
sythesis, an arylhydrazine 77 combines with an enolizable ketone 78 to form the 
hydrazone 79. This hydrazone 79 undergoes a series of acid-catalyzed tautomerizations, 
rearrangements, and eliminations to produce the final substituted indoles 80. After 
performing a careful analysis on the mechanism of this reaction, Simoneau et al. 
recognized that the initial arylhydrazone 79 might alternatively be prepared by the 
reaction of arylhydrazine 77 with N-unsubstituted ketimine 74. Following the approach 
described earlier, imine 74 might arise from the nucleophilic addition of organometallic 
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reagents to nitriles. A new 3-component Fischer indole was thus successfully 
demonstrated by combining organometallic reagents, nitriles, and arylhydrazines. In 
effect, the useful and well-known 2-component Fischer indole reaction “evolved” into a 
new 3-component reaction. 
 
 
Scheme 1.12
36
 
 
 Another independent route to arylhydrazones like 79 was developed by Simoneau 
et al. by focusing on the properties of nitroalkanes.
47
 When treated with base, a 
nitroalkane 81 gives rise to a nitronate anion 82. When treated with strong acid, the 
nitronate anion 82 is protonated first to the aci-nitro species 83 and then to the iminium 
species 84. Upon hydrolysis, the iminium species 84 forms the carbonyl product 85. In 
theory, any of the intermediates 82-84 might give rise to the formation arylhydrazone 79. 
In reality, phenylhydrazine failed to react with nitronate 82. However, Simoneau et al. 
observed that a mixture of nitroalkane 81, sodium methoxide 86 and arylhydrazine 77, 
upon mild acidification and heating, produced the substituted indole 80 in good yield. 
23 
 
This finding offered another convenient access to the substituted indole motif that is 
found in many medicinally significant natural products.
48,49
  
 
 
Scheme 1.13
36
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CHAPTER 2 
A Practical and Inexpensive ‘Convertible’ Isonitrile for Use in 
Multicomponent Reactions 
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2.1 Background 
 The use of multicomponent reactions (MCRs) to generate complex small 
molecule arrays continues to play an important role in drug discovery and 
development.
1,2
 By concurrently forming several new bonds in a one-pot procedure and 
with high atom economy, MCRs provide rapid access to chemically diverse structures in 
an operationally simple manner. Recently, the ability to perform iterative
3
 as well as 
higher-order
4
 MCRs has significantly increased the molecular complexity that can be 
obtained in chemical libraries. 
 Isonitriles are key components in the design and development of many MCRs.
5,6
 
Isonitriles contain a unique divalent carbon atom, allowing them to take part in a broad 
range of chemical reactions involving both nucleophiles and electrophiles. MCRs using 
isonitriles as one component are very versatile,
5,7
 as can be seen in the Passerini and the 
Ugi reactions. In each case, the isonitrile input creates a secondary carboxamide group in 
the product. Because amides have low reactivity, mild methods for converting such 
amides into carboxylic acids or esters would enhance the utility of MCR products. The 
newly converted carboxylic acid or ester could, for example, become an input in another 
MCR or participate in other chemical transformations to diversify the chemical libraries 
or to synthesize specific targets. 
 To date, several “convertible” isonitriles have been developed. The most well-
known and commonly-used “convertible” isonitrile is 1-cyclohexenylisonitrile 19, which 
was developed by Armstrong and demonstrates excellent utility in the Ugi reaction 
(Scheme 2.1).
8,9
 The use of 19 leads to a cyclohexenamide group in the Ugi product 90. 
Subsequent hydrolysis of the cyclohexenamide in acidic environment leads to a 
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carboxylic acid product 91, whereas reaction of the cyclohexenamide in neat alcohol or 
thiol affords an ester 92a or thioester product 92b, respectively.  
 
 
Scheme 2.1
8
 
 
1-Cyclohexenylisonitrile has been widely used in the synthesis of many 
pharmaceutical agents and bioactive compounds. For example, Kalinski et al. recently 
used 19 in their synthesis of the oral antiplatelet agent clopidogrel (Scheme 1.3).
10
  
 Keating and Armstrong used 1-cyclohexenylisonitrile in a remarkable two-step 
synthesis of diverse 1,4-benzodiazepine-2,5-diones (BZDs), which have been identified 
as platelet aggregation inhibiting mimics of the arginine-glycine-aspartic acid (RGD) 
peptide sequence and have shown anticonvulsant, anxiolytic, and antitumor activities.
11
 
The Ugi product 96 was formed by the condensation of 19 with anthranilic acid 93, 
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amine 94, and aldehyde 95. Subsequent methanolysis using methanolic HCl and 
cyclization afforded 1,4-benzodiazepine-2,5-dione 97 (Scheme 2.2). 
 
 
Scheme 2.2
11,12
 
 
 The accepted mechanism for the conversion of Ugi products derived from 
isonitrile 19 to carboxylic acids or esters is depicted in Scheme 2.3.
8
 Protonation of 90 
leads to the N-acyliminium species 98. With the participation of the α-acylamino group, 
98 cyclizes and eliminates to give the munchnone 99. Subsequent ring opening by water 
or alcohol gives rise to the acid or ester product, respectively. It is known that the 
electron rich α-acylamino group plays an essential role in the formation of the 
munchnone 99.
13
 If the Ugi products do not contain an α-acylamino group or instead 
contain an α-formylamino group, no cyclization to the munchnone 99 occurs.  
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Scheme 2.3
8
 
 
The synthesis of 1-cyclohexenylisonitrile is quite laborious, and it is difficult to 
prepare in quantities larger than a few hundred milligrams.
13,14
 In addition to exhibiting 
vile odor, isonitrile 19 is unstable on storage and decomposes even when stored under 
argon at -30 °C.  
Besides isonitrile 19, several other “convertible” isonitriles have also been 
developed, including (β-isocyanoethyl)alkylcarbonates 100-103 developed by Ugi,13 and 
various fragrant oxazole- and benzoxazole-derived isonitriles 104-112 developed by 
Pirrung
14
 (Figure 2.1). While these isonitriles have all demonstrated utility in the Ugi 
reaction, none has been shown to be “convertible” in α-acyloxyamide (i.e., Passerini) 
products. Moreover isonitriles whose amides convert into esters create a new selectivity 
problem in Passerini reaction products, which already contain hydrolyzable ester 
functionality. 
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Figure 2.1 Some “Convertible” Isonitriles for MCRs 
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 We recognized that tert-butylisonitrile might serve as a useful convertible 
isonitrile in Passerini and related reactions. Among its many advantages, including low 
cost and commercial availability, tert-butylisonitrile gives rise in MCRs to N-tert-
butylamides, whose characteristic NMR singlet simplifies the analysis of multicomponent 
reaction products. We now demonstrate that nitrosation of various N-tert-butylamides 
affords carboxylic acids under non-hydrolytic conditions. 
 The nitrosation of secondary carboxamides and thermal transformations of the 
derived N-alkyl-N-nitrosamides, first investigated systematically by White,
15,16
 have been 
the subject of extensive mechanistic study over the past half-century, including recent 
theoretical calculations.
17
 N-Alkyl-N-nitrosamides undergo a highly solvent-dependent 
thermal rearrangement at 80–100°C via diazenes to products derived either from 
diazoalkane or carbocation intermediates. By controlling and/or intercepting such 
intermediates, our laboratory several years ago developed several new synthetic 
transformations of amines via their derived nitrosamides to alcohols, phosphotriesters 
alkenes, alkynes, enol acetates, and aldehydes (Scheme 2.4).
18–21
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Scheme 2.4
18–21
 
 
 Building on those earlier findings, we reasoned that upon rearrangement of N-
nitroso-N-tert-butylamides 133 to 134, the subsequent dissociation should strongly favor 
the carbocationic pathway shown in Scheme 2.5, thus achieving a mild amide-to-acid 
conversion while releasing innocuous gaseous byproducts nitrogen 137 and isobutene 
138. 
35 
 
 
Scheme 2.5 
 
 In support of this hypothesis, the nitrosation of N-cyclohexylamides has been 
reported in the literature to afford modest yields of carboxylic acids,
16
 but to the best of 
our knowledge nitrosation of secondary amides bearing tertiary alkyl substituents has not 
been described. The dealkylation of N-tert-butylamides 132 to acids 139 has only been 
achieved non-oxidatively using strong acids.
22–24
 
 
2.2 Results and Discussion 
 To test this hypothesis, a series of simple N-tert-butylamides were nitrosated 
using NaNO2 in 1:2 acetic acid/acetic anhydride (Method A) as first described by White. 
The results, shown in Table 2.1, established that nitrosation and rearrangement proceeded 
under mild conditions to afford the desired carboxylic acids in excellent yield.  
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Table 2.1 Nitrosation/Rearrangement of tert-Butylamides Leading to Carboxylic Acids
 a
 
________________________________________________________________________ 
 
a
 Conditions: 2 x 10 equiv NaNO2; 1:2 acetic acid/acetic anhydride, 0 °C, 3 h; then stirring 16 h at 
rt followed by concentration and partitioning between diethyl ether and aq NaHCO3.  
b
 Reported yields were corrected for small quantities (2–8%) of recovered starting material. 
c
 Control workups established that ca. 25% of this volatile product was lost by rotary evaporation 
during workup. 
________________________________________________________________________ 
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 Next a representative group of α-acyloxyamides 150a-e (Scheme 2.6) was 
prepared using the Passerini three-component reaction following standard procedures for 
reacting the appropriate carbonyl compound, carboxylic acid, and tert-butylisonitrile.
25
 
  
 
Scheme 2.6  
  
Initially, nitrosation of 150a-e was performed using Method A, which afforded 
variable results. The more sterically hindered Passerini compounds 150c-e reacted 
sluggishly, but cleanly, using Method A, with recovered starting materials being the only 
other products. Superior results were obtained using the more reactive nitrosating reagent 
N2O4 with sodium acetate in CCl4 (Method B). Much higher yields and complete 
conversion were achieved with amides 150c-e (Table 2.2). 
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Table 2.2 Conversion of Passerini Compounds 150 to Carboxylic Acids
 
 
________________________________________________________________________ 
 
- Method A: 2 x 10 equiv NaNO2; 1:2 acetic acid/acetic anhydride, 0 °C, 3 h; then stirring 16 h at 
rt followed by concentration and partitioning between diethyl ether and aq NaHCO3. 
- Method B: gaseous N2O4 bubbled (~2 bubbles/sec) for 5 min; CCl4, 0 °C, 3 h; then stirring 16 h 
at rt followed by concentration and partitioning between diethyl ether and aq NaHCO3. 
________________________________________________________________________ 
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Of particular interest was the fact that the tert-butylamides in 150a-e were 
transformed into the corresponding carboxylic acids 151a-e without affecting the 
carboxylic esters present in each substrate. Notably 150d, which incorporates two ester 
groups (one of which is sterically uncongested), was transformed into acid-diester 151d 
in excellent yield (Method B), thus highlighting the non-hydrolytic nature of this 
transformation. 
 Next a series of α-hydroxy-N-tert-butylamides 152a-c was prepared by a recently 
reported variation of the Passerini two-component reaction using boric acid as the 
Brønsted acid (Scheme 2.7).
26
 
 
 
Scheme 2.7 
 
 Method A was not compatible with these α-hydroxy-N-tert-butylamides. When 
152a was nitrosated under those conditions, acetylation of the free alcohol group afforded 
acetoxyacid 151e as the major product. However, Method B furnished the desired 
hydroxyacids 153a-c in modest to high yield (Table 2.3). 
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Table 2.3 Conversion of α-Hydroxy-N-tert-Butylamides to Carboxylic Acids 
________________________________________________________________________ 
 
________________________________________________________________________ 
 
 tert-Butylisonitrile has been widely used in Ugi four-component condensations, 
thus it was of interest to learn whether the derived secondary/tertiary diamides could be 
“converted” into the corresponding amidoacids. A test series of diamides was prepared 
(Figure 2.2) using tert-butylisonitrile following the standard Ugi protocol in methanol.
9
 
Somewhat surprisingly, we observed no nitrosation of diamide 154a using Method A 
conditions. To test whether steric effects at the tertiary amide group were a factor, 
diamides 154b and 154c were also subjected to Method A conditions, and in each case, 
starting material was recovered nearly quantitatively. Diamides 154d-e behaved 
similarly. 
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Figure 2.2 A Representative Group of Diamides 
 
 Nitrosations of 154a-e using the more potent nitrosating agent N2O4 (Method B) 
were also unpromising, affording at best trace quantities of acids along with (mostly) 
unreacted diamides and several uncharacterized byproducts.  
Difficulties in nitrosating N-cyclohexyl- and other sterically hindered amides 
have previously been reported by Vilarrasa et al. (Figure 2.3).
27
 When compounds 155-
157 were treated with N2O4 / NaOAc, no amounts of N-nitrosated products were detected. 
Substitution of pyridine for NaOAc had been previously shown to improve the nitrosation 
of some moderately hindered peptide bonds.
28,29
 However, when this substitution was 
applied for compounds 155-157, no significant improvement was observed.
27
  
 
 
Figure 2.3 Some Sterically Hindered Amides
27
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 The resistance of Ugi amides 154a-e to nitrosation made it possible to selectively 
deprotect a Passerini tert-butylamide in the presence of an Ugi tert-butylamide. 
Nitrosation of a 1:1 mixture of 150b and 154e using Method A afforded 151b in 54% 
yield (96% based on recovered 150b). Compound 154e was recovered quantitatively. 
 Hulme et al. recently reported an alternative use of n-butylisonitrile, expedited 
with microwaves, as a convertible isonitrile for heterocycle synthesis.
30
 Therefore, it was 
of interest to determine whether n-butylisonitrile might serve as a convertible isonitrile 
for Ugi reactions by enabling an amide-to-ester conversion of the corresponding N-(n-
butyl)amide product. Two test diamides 158a-b were prepared (Scheme 2.8) using n-
butylisonitrile following the standard Ugi protocol in methanol.
9
 Ugi compounds 158a-b 
underwent smooth nitrosation using Method A to afford the corresponding N-
nitrosoamides 159a-b following the standard workup. Upon heating to reflux in hexanes, 
the desired n-butylesters 160a and 160b were produced in 80% and 83% overall yield, 
respectively. This finding offered another convenient access to the α-amino ester motif 
that is found in many pharmaceutical agents and bioactive compounds, including the oral 
antiplatelet agent clopidogrel 23,
10
 the general anaesthetic agent for large animals 
carfentanil 161,
31
 the fungicide metalaxyl 162,
32
 the herbicide benzoylprop-ethyl 163,
33
 
and the lipoprotein(a) assembly inhibitor 164
34
 (Figure 2.4). 
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Scheme 2.8 
  
 
 
Figure 2.4 Some Pharmaceutical Agents Containing α-Amino Ester Motif 
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In summary, the studies presented herein demonstrate that tert-butylisonitrile can 
serve as an inexpensive, efficient, and readily available “convertible isonitrile” in 
Passerini and related multicomponent reactions. To the best of our knowledge, tert-
butylisonitrile is the first isonitrile whose amide-to-acid “conversion” is compatible with 
preexisting ester functionality in MCR products. We further show that n-butylisonitrile 
may provide a viable alternative to other convertible isonitriles for amide-to-ester 
transformations in Ugi MCR products. 
 
2.3 Experimental Procedures 
General Procedures 
1
H NMR and 
13
C NMR spectra were taken on a Bruker ARX300, Varian 
Mercury-300, Varian Inova-400, or Varian Inova-500 spectrometer using CDCl3 with 
0.05% v/v TMS as solvent.  Spectra were recorded in δ (ppm) and were referenced to 
TMS (0.00 ppm for 
1
H NMR) and CDCl3 (77.23 ppm for 
13
C NMR).  IR spectra were 
obtained on a Mattson Instruments Galaxy Series FT-IR spectrometer and were recorded 
in wavenumbers (cm
-1
). Melting points were measured using a Thomas Hoover Uni-melt 
capillary melting point apparatus. Mass spectra were measured at the Life Sciences Core 
Laboratories Center using ABI/MDS Sciex 4000 Q Trap or Waters Synapt HDMS. 
Chemicals were obtained from Aldrich, Fluka, Fisher, or Mallinckrodt and used as 
received unless specified. 
Preparation of α-Acyloxy-N-(tert-Butyl)amides 
 A literature procedure for the Passerini 3-component reaction was followed.
25
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Preparation of α-Hydroxy-N-(tert-Butyl)amides 
 A literature procedure for the Passerini 2-component reaction was followed.
26
 
Preparation of α-Acylamino-N-(tert-Butyl)amides and α-Acylamino-N-(n-Butyl)amides 
 A literature procedure for the Ugi reaction was followed.
9
 
Nitrosation Using Method A 
 The carboxamide (0.25 mmol) was dissolved in 1:2 acetic acid:acetic anhydride 
(2.5 mL) in a 25 mL round-bottom flask (RBF). After cooling the solution to 0 
o
C, 
NaNO2 (2.5 mmol, 10 equiv) was added in one portion.  The resulting suspension was 
stirred vigorously at 0 
o
C for 30 min, then another portion of NaNO2 (2.5 mmol) was 
added. The suspension was stirred vigorously at 0 
o
C for another 2.5 h. The ice bath was 
removed and the reaction mixture was stirred vigorously at rt for 16 h, then concentrated 
using a rotary evaporator and neutralized by slow addition of saturated NaHCO3 to pH 8. 
The aqueous phase was extracted with ether (4 x 10 mL), then cooled to 0 
o
C and 
carefully acidified with ice-cold 1M HCl solution to pH 2 and immediately extracted with 
ether (4 x 15 mL). The combined ether layers were washed with brine, dried (MgSO4), 
filtered and concentrated in vacuo to afford the desired product. 
Nitrosation Using Method B 
 The carboxamide (0.25 mmol) was dissolved in CCl4 (2.5 mL) in a 25 mL round-
bottom flask. The solution was cooled to 0
o 
C, then NaOAc (0.75 mmol) was added. 
Stiring was stopped while gaseous N2O4 was bubbled into the cold suspension using a 5” 
disposable pipette (~2 bubbles/sec) for 5 min. The mixture was stirred vigorously for 3 h 
at 0 
o
C, then for 16 h at rt. The bulk of solvent was removed using a rotary evaporator 
46 
 
and the product isolated as in Method A. (For compounds 152a-c, the acidified aqueous 
layer was saturated with NaCl before ether extraction to maximize the yield). 
1
H NMR, 
13
C NMR, IR, MS and Other Physical Characterization Data for New 
Products 
NOTE - Passerini 152a and acid 151e are known but their spectral data are not available 
on databases; therefore, copies of their 
1
H NMR spectra are also provided. 
Passerini 150b: Recrystallized with hexane to afford a white crystal (63%, m.p. 
93 
o
C). IR (CH2Cl2) 3315(m), 2967(m), 2932(m), 1742(s), 1667(s), 1529(m); ESI-MS 
(CH3OH) 278.14 (M+H), 300.13 (M+Na). 
Passerini 150c: Recrystallized with ethyl ether to afford a white crystal (22%, 
m.p. 130-131 
o
C). IR (CH2Cl2) 3332(s), 3061(m), 2965(s), 1716(s), 1660(s), 1539(s); 
ESI-MS (CH3OH) 340.16 (M+H), 362.15 (M+Na). 
Passerini 150d: Purified with 1:3 ethyl acetate:hexane (Rf=0.3) to afford a white 
solid (47%, m.p. 63-64 
o
C). IR (CH2Cl2) 3324(m), 2966(s), 1740(s), 1674(s), 1529(s); 
ESI-MS (CH3OH) 363.8 (M+H), 385.5 (M+Na). 
Passerini 150e: Recrystallized with hexane to afford a white crystal (59%, m.p. 
110.5-111 
o
C). IR (CH2Cl2) 3363(m), 2941(s), 1734(s), 1662(s), 1522(s); ESI-MS 
(CH3OH) 242.14 (M+H), 264.14 (M+Na). 
Passerini 152c: Purified with 1:3 ethyl acetate:hexane (Rf=0.2) to afford clear oil 
(42%): IR 3384(s), 2925(s), 2857(m), 1655(s), 1530(s); ESI-MS (CH3OH) 230.4 (M+H), 
252.4 (M+Na). 
Acid 151c: general procedure afforded a yellow solid m.p. 100-101 
o
C: IR 
(CH2Cl2) 3028(m), 2931(m), 1723(s), 1602(m); ESI-MS (CH3OH) 283.08 (M-H). 
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Acid 151d: general procedure afforded a yellow oil: IR (CH2Cl2) 3467(m), 
3027(m), 2955(m), 1739(s); ESI-MS (CH3OH) 309.4 (M+H), 331.4 (M+Na). 
Ugi 154a: Purified with 1:3 ethyl acetate:hexane (Rf=0.3) to afford a clear sticky 
gel (43%): IR (CH2Cl2) 3414(s), 3062(m), 2965(m), 1680(s), 1623(s), 1514(m); ESI-MS 
(CH3OH) 429 (M+H), 451.5 (M+Na). 
Ugi 154b: Purified with 1:3 ethyl acetate:hexane (Rf=0.2) to afford a clear sticky 
gel (28%): IR (CH2Cl2) 3321(m), 3062(m), 2967(m), 1678(s), 1635(s), 1543(m); ESI-MS 
(CH3OH) 367.4 (M+H), 389.5 (M+Na). 
Ugi 154c: Purified with ethyl acetate (Rf=0.4) to afford a clear sticky gel (22%): 
IR (CH2Cl2) 3315(m), 3026(m), 2966(s), 1678(s), 1634(s), 1541(m); ESI-MS (CH3OH) 
291.4 (M+H), 313.4 (M+Na). 
Ugi 154d: Purified with 1:3 ethyl acetate:hexane (Rf=0.3) to afford a light yellow 
gel (16%): IR 3312(m), 3026(m), 2961(s), 2872(m), 1683(s), 1617(s), 1540(m); ESI-MS 
(CH3OH) 395.2562 (M+H). 
Ugi 154e: Purified with 2:3 ethyl acetate:hexane (Rf=0.3) to afford a white solid 
(84%, m.p. 60-62 
o
C): IR (CH2Cl2) 3316(m), 3062(m), 2968(m), 1683(s), 1627(s), 
1547(m); ESI-MS (CH3OH) 401.5 (M+H), 423.5 (M+Na). 
Ugi 158a: Purified with 2:3 ethyl acetate:hexane (Rf=0.2) to afford a white solid 
(69%, m.p. 113-113.5 
o
C): IR (CH2Cl2) 3296(s), 3061(m), 2957(m), 1656(s), 1632(s), 
1560(m); ESI-MS (CH3OH) 401.5 (M+H), 423.5 (M+Na). 
Ugi 158b: Recrystallized with toluence to afford a white crystal (29%, m.p. 116-
117
o
C): IR (CH2Cl2) 3297(s), 3087(m), 2960(m), 1682(s), 1626(s), 1560(m); ESI-MS 
(CH3OH) 339.4 (M+H), 361.4 (M+Na). 
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Ester 160a: general procedure afforded yellow oil: IR 3062(m), 2959(s), 1743(s), 
1647(s); ESI-MS (CH3OH) 402.5 (M+H), 424.5 (M+Na). 
Ester 160b: general procedure afforded yellow oil: IR 3063(m), 2959(s), 1739(s), 
1654(s). ESI-MS (CH3OH) 340.4 (M+H), 362.4 (M+Na). 
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Figure 2.5 
1
H NMR Spectrum of Passerini 150b 
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Figure 2.6 
13
C NMR Spectrum of Passerini 150b 
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Figure 2.7 
1
H NMR Spectrum of Passerini 150c 
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Figure 2.8 
13
C NMR Spectrum of Passerini 150c 
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Figure 2.9 
1
H NMR Spectrum of Passerini 150d 
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Figure 2.10 
13
C NMR Spectrum of Passerini 150d 
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Figure 2.11 
1
H NMR Spectrum of Passerini 150e 
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Figure 2.12 
13
C NMR Spectrum of Passerini 150e 
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Figure 2.13 
1
H NMR Spectrum of Passerini 152a 
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Figure 2.14 
1
H NMR Spectrum of Passerini 152c 
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Figure 2.15 
13
C NMR Spectrum of Passerini 152c 
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Figure 2.16 
1
H NMR Spectrum of Acid 151c 
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Figure 2.17 
13
C NMR Spectrum of Acid 151c 
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Figure 2.18 
1
H NMR Spectrum of Acid 151d 
63 
 
 
Figure 2.19 
13
C NMR Spectrum of Acid 151d 
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Figure 2.20 
1
H NMR Spectrum of Acid 151e 
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Figure 2.21 
1
H NMR Spectrum of Ugi 154a 
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Figure 2.22 
1
H NMR Spectrum of Ugi 154b 
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Figure 2.23 
13
C NMR Spectrum of Ugi 154b 
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Figure 2.24 
1
H NMR Spectrum of Ugi 154c 
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Figure 2.25 
13
C NMR Spectrum of Ugi 154c 
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Figure 2.26 
1
H NMR Spectrum of Ugi 154e 
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Figure 2.27 
1
H NMR Spectrum of Ugi 158a 
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Figure 2.28 
13
C NMR Spectrum of Ugi 158a 
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Figure 2.29 
1
H NMR Spectrum of Ugi 158b 
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Figure 2.30 
13
C NMR Spectrum of Ugi 158b 
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Figure 2.31 
1
H NMR Spectrum of Ester 160a 
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Figure 2.32 
13
C NMR Spectrum of Ester 160a 
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CHAPTER 3 
A Simple, General Synthesis of Carbonimidic Dichlorides 
 
Reproduced in part with permission from 
Tetrahedron Letters 2012, 53, 4536–4537 
Copyright © 2012 by Elsevier Ltd. 
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3.1 Background 
 Carbonimidic dihalides (also known as isonitrile dihalides), which have the 
general structure R−N=CX2 (where X typically = Br or Cl), have recently attracted 
attention not only as protecting groups for isonitriles,
1
 but also as building blocks for 
more complex molecular architectures.
2
 
Carbonimidic dibromides and carbonimidic dichlorides are generally stable at 
room temperature,
3
 while several types of carbonimidic difluorides dimerize at ambient 
temperature (Scheme 3.1).
4
 Carbonimidic diiodides are virtually unknown because they 
are not stable and dissociate into iodine and the corresponding isonitriles (Scheme 3.2).
3
 
This characteristic has been used to easily transform a carbonimidic dihalide such as 167 
into the corresponding isonitrile 169 by reacting it with potassium iodide. 
 
 
Scheme 3.1 
 
 
 
Scheme 3.2
3
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Carbonimidic dihalides have a strong, unpleasant odor, though not as unpleasant 
as that of isonitriles.
5
 The vapors of carbonimidic dihalides cause extreme irritation to the 
eyes and may lead to temporary loss of vision. 
Carbonimidic dihalides can be found in many natural products. For example, 
König et al. recently isolated five sesquiterpene carbonimidic dichlorides 170-174 from 
the Australian sponge Ulosa spongia (Figure 3.1).
6
  
 
 
Figure 3.1 Some Sesquiterpene Carbonimidic Dichlorides Isolated from the Australian 
Sponge Ulosa Spongia
6
 
 
 The first carbonimidic dihalide was synthesized by Sell and Zierold in 1874 when 
they obtained phenylcarbonimidic dichloride 176 from the reaction of phenyl-
isothiocyanate 175 and chlorine in chloroform at 0 
o
C (Scheme 3.3).
7,8
 This method 
proved to be general.
8,9
 Nef later observed that the reaction reported by Sell and Zierold 
also contained chlorination products of the benzene ring.
8,10
 However, when carbon 
tetrachloride was used as the solvent, the reaction gave no chlorination products of the 
ring.  
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Scheme 3.3 
 
The chlorination of phenylisothiocyanate 175 was discovered by Zumach et al. to 
proceed in two steps (Scheme 3.4).
9
 An N-(chloro-chlorothiomethylene)carbonamide 177 
was first formed by addition of chlorine in a strongly exothermic reaction. Further 
chlorination led to the elimination of sulfur dichloride to afford phenylcarbonimidic 
dichloride 176. No heat evolution was observed in the second step. The comparable 
addition of bromine to phenylisothiocyanate 175 was investigated by Freund but did not 
afford phenylcarbonimidic dibromide; only bromine adducts were observed.
9,11
  
 
 
Scheme 3.4 
 
Another method of synthesis of carbonimidic dihalides is the addition of halogen 
to isonitriles (Scheme 3.5).
8,9
 The addition of chlorine to isonitriles was first reported by 
Nef in 1892. When ethylisonitrile 180 and phenylisonitrile 182 were treated with chlorine 
in chloroform at room temperature, ethylcarbonimidic dichloride 181 and phenyl-
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carbonimidic dichloride 174 were obtained, respectively. Likewise, the comparable 
addition of bromine to isonitriles 178 afforded carbonimidic dibromides 179.  
 
 
Scheme 3.5 
 
Sulfuryl chloride can also be used as the chlorinating agent instead of chlorine in 
the synthesis of carbonimidic dichlorides from isonitriles.
8
 This replacement was first 
done by Nef when he obtained ethylcarbonimidic dichloride 181 from the reaction 
between ethylisonitrile 180 and sulfuryl chloride 183 in ethyl ether at room temperature 
(Scheme 3.6). However, this method of synthesis of carbonimidic dichlorides has 
received little attention and to the best of our knowledge, no further studies have been 
conducted. 
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Scheme 3.6
8
 
 
Carbonimidic dichlorides can also be obtained from the reaction of isocyanates 
and phosphorus pentachloride (Scheme 3.7).
9
 When lower aliphatic and cycloaliphatic 
isocyanates 185 were treated with 1 equiv of phosphorus pentachloride 186 in 
chlorobenzene at 20 to 50 °C, the corresponding carbonimidic dichlorides 167 were 
obtained in good yields. When long-chain aliphatic isocyanates were treated with the 
same reaction conditions, side-chain chlorination concurrently occurred. Aromatic 
isocyanates 188 only reacted with phosphorus pentachloride 186 at temperatures above 
100 
o
C. The corresponding carbonimidic dichlorides were obtained only in low yield. The 
main products were carbodiimides 189. 
 
 
Scheme 3.7 
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Carbonimidic dihalides have been used as protecting groups for isonitriles, and 
they can be easily converted back to the parent isonitriles by reacting them with iodide, 
triethylphosphine, LiAlH4, or electrochemical reduction.
1
 For example, Baldwin et al. 
turned the isonitrile 192 into the corresponding carbonimidic dibromide 193 to protect the 
isonitrile functionality from the epoxidation conditions in their total synthesis of the 
antibiotic (±)-trichoviridin 196, a naturally occurring epoxy-isonitrile (Scheme 3.8).
12
 
 
 
Scheme 3.8 
 
Activated by two halogen atoms, the C=N double bond in carbonimidic dihalides 
could be subjected to two nucleophilic additions, possibly in sequential manner (Scheme 
3.9).
2
 This unusual characteristic of carbonimidic dihalides has led to their use as 
building blocks for more complex molecular architectures. 
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Scheme 3.9
2
 
 
El Kaim et al. recently used carbonimidic dibromides in their 3-component 
strategy to afford tetrazole and triazole scaffolds (Scheme 3.10).
2
 Tetrazoles 201 were 
synthesized by the addition of sodium azide to carbonimidic dibromides 179, followed by 
electrocyclization and a Suzuki coupling. Triazole 207 was synthesized by the addition of 
tetrazole 204 to carbonimidic dibromide 203, followed by Huisgen rearrangement and a 
Suzuki coupling. 
 
 
Scheme 3.10
2
 
 
Yu et al. recently developed a one-pot method for the synthesis of 2-amino-
benzimidazoles from carbonimidic dichlorides and amines (Scheme 3.11).
13
 Such 
benzimidazoles display significant biological activity and compose the core structure of 
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many commercial drugs such as vermox, fenbendazole, nocodazole, and mizolastine. The 
copper-catalyzed condensation of carbonimidic dichlorides 208 and 2 equiv of amines 
209 formed 2-aminobenzimidazoles 210. 
 
 
Scheme 3.11
13
 
 
Du Bois et al. recently used a carbonimidic dichloride in their total synthesis of a 
paralytic agent (+)-saxitoxin associated with oceanic red tides (Scheme 3.12).
14
 
Compound 216 was formed by the condensation of carbonimidic dichloride 214, amine 
213, and amine 215. Subsequent modification afforded (+)-saxitoxin 217. 
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Scheme 3.12 
 
Carbonimidic dibromides can usually be prepared by simple addition of elemental 
bromine to the isonitrile. However, the comparable addition of elemental chlorine (Cl2) to 
isonitriles is not a generally useful reaction with alkylisonitriles, since free-radical 
processes generally produce alkyl chloride byproducts resulting from C–H substitution.9 
 Here we report that the chlorination of isonitriles 178 using sulfuryl chloride 
rapidly and selectively furnishes the corresponding carbonimidic dichlorides 167 
(Scheme 3.13). Besides being readily available, inexpensive, and quite convenient to use, 
sulfuryl chloride is also easy to purify and manipulate in small quantities for benchtop 
experimentation. 
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Scheme 3.13 
 
 Sulfuryl chloride has long been known as both an excellent chlorinating and 
sulfonylating agent for aromatic compounds, depending on the choice of experimental 
conditions.
15
 Both addition and substitution processes have been observed. For example, 
naphthalene 218 can be made to react with sulfuryl chloride in different reaction 
conditions to afford different chlorinated products (Scheme 3.14). At 80 
o
C, 1,2,3,4-
tetrachloro-1,2,3,4-tetrahydronaphthalene 219 is collected as the main product, whereas 
at 100-140 
o
C, 1,4-dichloronaphthalene 220 is obtained as the main product. When 
aluminum chloride is used as a catalyst at room temperature, the reaction affords 1-
chloro-naphthalene 221. 
 
Scheme 3.14
15
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Sulfuryl chloride also produces chlorination of aliphatic hydrocarbons under ionic 
conditions using Lewis acid catalysts, or under free radical conditions in the presence of a 
suitable catalyst (peroxides) or light.
15
 However, in the absence of such free radical 
initiators, aliphatic chlorination can largely be suppressed at low temperatures. This 
exquisite control of product outcomes, as summarized in a recent review,
16
 has led to a 
resurgence of interest in sulfuryl chloride on the part of academic and industrial 
researchers.
17,18
 
 
3.2 Results and Discussion 
 Using cyclohexylisonitrile 202a as a test case, neat SO2Cl2 (1 equiv) was added 
dropwise to a stirred CHCl3 solution (1.0 M) of the isonitrile at -20 ºC under nitrogen, 
and the reaction mixture was warmed to room temperature (15–30 min total reaction 
time) (Scheme 3.15). The desired carbonimidic dichloride 222a was obtained in nearly 
quantitative yield and exhibited the expected 9:6:1 ratio of M:M+2:M+4 peaks 
characteristic of two chlorine atoms in the structure. Applying the same procedure to n-
butylisonitrile 202b led to product 222b contaminated with 10–15% chain-chlorinated 
byproducts. However, by lowering the reaction temperature to -45 ºC and pre-diluting the 
SO2Cl2 with CHCl3, 222b was obtained ca 95% pure. The latter reaction condition was 
thus chosen as the preferred method for the synthesis of carbonimic dichlorides from 
isonitriles. 
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Scheme 3.15 
 
 Chlorinations of representative isonitriles 202a–f using SO2Cl2 at -45 ºC are 
summarized in Table 3.1 and illustrate the broad scope and efficiency of the method. 
Both aliphatic and aromatic isonitriles were readily converted into the corresponding 
dichlorides in excellent yield. Although carbonimidic dichlorides 222a–e have previously 
been synthesized (as referenced in Table 3.1), very little spectroscopic or physical 
characterization (other than IR and mp) data were provided in earlier publications. All 
products 222a–f were fully characterized by 1H NMR, 13C NMR, IR, and either chemical 
ionization mass spectrometry (CIMS) or electron impact mass spectrometry (EIMS). The 
product carbonimidic dichlorides could be stored neat at -20 ºC for up to 4–5 days 
without appreciable decomposition, but NMR samples deteriorated appreciably upon 
standing at room temperature after 1–2 days. 
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Table 3.1 Synthesis of Isonitrile Dichlorides Using Sulfuryl Chloride
19–25
 
________________________________________________________________________ 
 
________________________________________________________________________ 
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 When dichloride 222c was analyzed using CIMS, no parent ions could be 
detected, likely because of the facile fragmentation of protonated 222c shown in Scheme 
3.16. However the EIMS spectrum of 222c revealed the expected M, M+2 and M+4 
pattern of parent ions, as well as characteristic fragment ions resulting from both α-
cleavage and inductive cleavage pathways. 
 
 
Scheme 3.16 
 
 
 
Scheme 3.17 
 
Data in Table 3.1 confirm that the reaction is compatible with other functionality, 
including carboxylic esters. Moreover, no aromatic chlorination products were detected. 
In a competition experiment between cyclohexylisonitrile 202a and 1-decene 225, 
dichloride 222a was formed exclusively (94%) and 1-decene 225 was returned 
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unchanged, indicating high selectivity for chlorine addition to the isonitrile in the 
presence of an alkene (Scheme 3.17). Furthermore, isonitriles 202d–f selectively 
underwent addition in preference to substitution, even in the presence of activated methyl 
and methylene groups, such as CH3–Ar in 202d, –SO2CH2– in 202e, and –CH2CO2Et in 
202f. 
 
3.3 Experimental Procedures 
Representative Procedure for the Chlorination of Isonitriles Using SO2Cl2 
 A magnetically-stirred CHCl3 solution of isonitrile (0.7– 1.0 mmol) under N2 in 
an oven-dried 25 mL round-bottom flask was cooled in a dry ice-CHCl3 bath to -45 ºC. A 
solution of freshly distilled SO2Cl2 (1 equiv) in CHCl3 (1 M) was added dropwise via 
microsyringe over 10 min. The resulting solution was stirred for 10 min, then allowed to 
warm to rt. The desired product was obtained by concentrating the solution on a rotary 
evaporator and briefly exposing the residual oil to a vacuum line (0.1–0.25 torr, 1–2 min) 
to remove last traces of solvent. The product carbonimidic dichlorides were characterized 
without further purification. 
1
H NMR, 
13
C NMR, IR, and MS for Dichloride Products 
 Cyclohexylcarbonimidic Dichloride 222a: 
1H NMR δ 3.52–3.58 (m, 1 H), 1.22–
1.88 (m, 10 H); 
13
C NMR δ 121.7, 63.9, 32.2, 25.4, 24.2; IR (cm-1) 1644; CIMS m/z 180 
(MH
+
), 182 (MH
+
+2), 184 (MH
+
+4). 
n-Butylcarbonimidic Dichloride 222b: 
1H NMR δ 3.49 (t, 2 H, J = 6.9 Hz), 1.59–
1.65 (m, 2 H), 1.36–1.40 (m, 2 H), 0.94 (t, 3 H, J = 7.4 Hz); 13C NMR δ 123.4, 54.6, 
31.3, 20.3, 13.6; IR (cm
-1
) 1654; CIMS m/z 154 (MH
+
), 156 (MH
+
+2), 158 (MH
+
+4). 
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 tert-Butylcarbonimidic Dichloride 222c: 
1
H NMR δ 1.39 (s, 9 H); 13C NMR δ 
116.4, 59.9, 28.5; IR (cm
-1
) 1648; EIMS m/z 153 (M
+
), 155 (M
+
+2), 157 (M
+
+4); 138, 
140, 142 (loss of CH3); 57 (base peak). 
 (2-Methylphenyl)carbonimidic Dichloride 222d: 
1
H NMR δ 7.25–7.17 (m, 3 H), 
7.13 (td, 1 H, J = 7.5, 1.4 Hz), 6.82 (dd, 1 H, J = 7.8, 1.3 Hz), 2.17 (s, 3H); 
13
C NMR δ 
144.5, 130.6, 128.4, 126.4, 125.9, 118.9, 17.6; IR (cm
-1
) 1647; CIMS (electron impact, 
m/z): 188 (MH
+
), 190 (MH
+
+2), 192 (MH
+
+4). 
 {[(4-Methylphenyl)sulfonyl]methyl}carbonimidic Dichloride 222e: 
1
H NMR δ 
7.83 (d, 1 H, J = 8.3 Hz), 7.39 (d, 1 H, J = 8.0 Hz), 4.79 (s, 2 H), 2.47 (s, 3 H); 
13
C NMR 
δ 145.7, 134.0, 129.9, 129.0, 128.8, 73.9, 21.7; IR (cm-1) 1650; CIMS m/z 266 (MH+), 
268 (MH
+
+2), 270 (MH
+
+4). 
 Ethyl[(dichloromethylidene)amino]acetate 222f: 
1
H NMR δ 4.29 (s, 2 H), 4.26 (q, 
2 H, J = 7.2 Hz), 1.30 (t, 3 H, J = 7.2 Hz); 
13
C NMR δ 167.3, 129.9, 61.7, 55.6, 44.1, 
14.1; IR (cm
-1
) 1662; CIMS m/z 184 (MH
+
), 186 (MH
+
+2), 188 (MH
+
+4). 
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Figure 3.2 
1
H NMR Spectrum of Cyclohexylcarbonimidic Dichloride 222a 
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Figure 3.3 
13
C NMR Spectrum of Cyclohexylcarbonimidic Dichloride 222a 
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Figure 3.4 IR Spectrum of Cyclohexylcarbonimidic Dichloride 222a 
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Figure 3.5 Mass Spectrum of Cyclohexylcarbonimidic Dichloride 222a 
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Figure 3.6 
1
H NMR Spectrum of n-Butylcarbonimidic Dichloride 222b 
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Figure 3.7 
13
C NMR Spectrum of n-Butylcarbonimidic Dichloride 222b 
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Figure 3.8 IR Spectrum of n-Butylcarbonimidic Dichloride 222b 
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Figure 3.9 Mass Spectrum of n-Butylcarbonimidic Dichloride 222b 
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Figure 3.10 
1
H NMR Spectrum of tert-Butylcarbonimidic Dichloride 222c 
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Figure 3.11 
13
C NMR Spectrum of tert-Butylcarbonimidic Dichloride 222c 
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Figure 3.12 IR Spectrum of tert-Butylcarbonimidic Dichloride 222c 
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Figure 3.13 Mass Spectrum of tert-Butylcarbonimidic Dichloride 222c 
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Figure 3.14 
1
H NMR Spectrum of (2-Methylphenyl)carbonimidic Dichloride 222d 
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Figure 3.15 
13
C NMR Spectrum of (2-Methylphenyl)carbonimidic Dichloride 222d 
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Figure 3.16 IR Spectrum of (2-Methylphenyl)carbonimidic Dichloride 222d 
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Figure 3.17 Mass Spectrum of (2-Methylphenyl)carbonimidic Dichloride 222d 
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Figure 3.18 
1
H NMR Spectrum of {[(4-Methylphenyl)sulfonyl]methyl}carbonimidic 
Dichloride 222e 
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Figure 3.19 
13
C NMR Spectrum of {[(4-Methylphenyl)sulfonyl]methyl}carbonimidic 
Dichloride 222e 
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Figure 3.20 IR Spectrum of {[(4-Methylphenyl)sulfonyl]methyl}carbonimidic 
Dichloride 222e 
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Figure 3.21 Mass Spectrum of {[(4-Methylphenyl)sulfonyl]methyl}carbonimidic 
Dichloride 222e 
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Figure 3.22 
1
H NMR Spectrum of Ethyl[(dichloromethylidene)amino]acetate 222f 
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Figure 3.23 
13
C NMR Spectrum of Ethyl[(dichloromethylidene)amino]acetate 222f 
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Figure 3.24 IR Spectrum of Ethyl[(dichloromethylidene)amino]acetate 222f 
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Figure 3.25 Mass Spectrum of Ethyl[(dichloromethylidene)amino]acetate 222f 
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CHAPTER 4 
Studies on the Synthesis of Amidoximes from Nitroalkanes 
 
Reproduced in part with permission from 
Tetrahedron 2011, 67, 10208–10211 
Copyright © 2011 by Elsevier Ltd. 
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4.1 Background 
 The single reactant replacement (SRR) approach to evolving new MCRs relies on 
identifying reactants that possess similar reactivity elements. The central role of the 
synthetic chemist is to recognize or elucidate such reactivity elements, which may 
sometimes be embodied in unusual reactants. In 2007, Simoneau et al. in our group 
realized that the intermediates in the Nef reaction of nitroalkanes, as shown in Scheme 
1.13, may behave similarly to imines because they embody the C=N group.
1
 If so, such 
inputs might be useful in the Ugi reaction or Fisher indole synthesis (Scheme 4.1). The 
derived nitronate anion 82 from nitroalkane 81 might be transformed to the 
monoprotonated aci-nitro species 83 or to the di-protonated iminium species 84. 
Subsequent amine addition or hydrazine addition, followed by N/N interchange, could 
produce imine 52 or arylhydrazone 79, respectively.  
 
 
Scheme 4.1
1
 
 
 Simoneau then went on to develop a new synthesis of substituted indoles from 
nitroalkanes and arylhydrazines in the presence of base, as described in Chapter 1.
2
 This 
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indole synthesis was inspired by two early patents reporting successful nucleophilic 
additions of thiols 227 to nitronates 226 leading to thiohydroximate esters 231 (Scheme 
4.12).
3–6
 Although no mechanism was proposed in the patents, one likely sequence of 
transformations is depicted in Scheme 4.2.
7
 
 
 
Scheme 4.2
7
 
  
We wondered whether the direct reaction of primary or secondary amines 232 
with nitronates 226 or with thiohydroximate esters 231 would afford the corresponding 
amidoximes 233 (Scheme 4.3). Such amidoximes are of considerable medicinal interest. 
Besides being involved in the biosynthesis of NO, they display potent pharmacological 
activity as anticoagulants, platelet inhibitors, antimicrobial agents and matrix 
metalloprotease inhibitors.
8,9
 
 
 
Scheme 4.3 
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Scheme 4.4
10
 
 
Currently, amidoximes may be prepared by many different routes, as summarized 
in a recent review by Katritzky et al. (Scheme 4.4).
10
 Of these routes, the most 
convenient source of amidoximes is the reaction of the corresponding nitriles 234 with 
hydroxyamine 235 (Scheme 4.5).
11–13
 A successful synthesis of amidoximes from 
nitroalkanes would add a useful new route to the preparation of amidoximes. 
 
 
Scheme 4.5 
 
  
126 
 
4.2 Results and Discussion 
Using 1-nitropropane as a prototype, we first explored the direct reaction of 1-
nitropropane with nucleophilic amines. After numerous attempts, however, we were 
unable to identify conditions under which a primary or secondary amine (n-butylamine, 
aniline, pyrrolidine) would react with 1-nitropropane either neat or in a protic (methanol) 
or aprotic (DMSO) solvent, even at elevated temperatures, to form detectable quantities 
of the corresponding amidoxime. 
We then turned our attention to the indirect route to amidoximes from the 
corresponding amines and thiohydroximate esters. We successfully prepared the 
thiohydroximate ester 239 using 1-nitropropane 237 and thiophenol 238 according to 
published conditions (NaOCH3 – CH3OH, reflux) (Scheme 4.6).
3–6
 
 
 
Scheme 4.6 
 
Given that 239 is an oximino analogue of a thioester, we expected it to react 
smoothly with an amine nucleophile to furnish the corresponding amidoxime 241. 
However, the reaction of 239 with aniline 240 (CH3OH, reflux) was extremely sluggish, 
and afforded a complex mixture of products (Scheme 4.7). Besides obtaining the hoped-
for propionamidoxime 241, we also identified the corresponding N,N’-diphenylpropion-
amidine 242. Both products were formed in low yield.  
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Scheme 4.7 
 
 Control experiments established that the amidine 242 was derived from 241 and 
240 (Scheme 4.8). While amidines have been prepared by reductive deoxygenation of 
amidoximes,
14,15
 to our knowledge the transformation of 241 into N,N’-diphenylpropion-
amidine 242 appeared to be the first example of an amidoxime-to-amidine transformation 
by nucleophilic addition of an amine and elimination of NH2OH. 
 
 
Scheme 4.8 
 
 Taken together, the surprisingly low reactivity of thiohydroximates and the 
unexpected susceptibility of amidoximes to further nucleophilic addition by amines 
indicated that the thiohydroximate pathway from nitroalkanes would not likely afford a 
viable route to amidoximes.  
 We decided to revisit the reaction of nitronates with amines, and considered the 
possibility of boosting the nucleophilicity of the amine component by metallation. A 
little-cited 1988 Russian report described the reaction of nitromethane 246 and 
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nitroethane 248 with magnesium tert-butylamide 245 (2.5 equiv, prepared using EtMgBr 
244 and tert-butylamine 243 at rt in THF) to afford the corresponding N-tert-butyl-
formamidoxime 247 and N-tert-butylacetamidoxime 249 in 40 and 45% yields, 
respectively (Scheme 4.9).
16
 
 
 
Scheme 4.9
16
 
 
 In applying the published procedure to various combinations of nitroalkanes and 
amines, we observed that EtMgCl metallated the amine component only sluggishly at rt. 
Therefore, to ensure complete metallation, the amines were added to EtMgCl in THF at 
reflux with continued heating until gas evolution ceased. The nitroalkanes were then 
added to the fully metallated amines. However, the yields of the resulted amidoximes 
were still mediocre, ranging from 26% to 46%. 
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 To ascertain whether the yield of amidoxime could be improved using different 
metallated amines, we studied the reaction of 1-nitropropane 237 and n-butylamine using 
various metallating agents (Scheme 4.10). The results are shown in Table 4.1. 
 
 
Scheme 4.10 
  
Table 4.1 Yields of N-(n-Butyl)propionamidoxime 251a from 1-Nitropropane Using 
Various Metallating Agents 
________________________________________________________________________ 
        Base         % Yield 
        EtMgCl       28  
     EtMgCl / cat. CuCl   27  
     n-BuLi     58  
     NaH     27 
________________________________________________________________________ 
 
As indicated in Table 4.1, magnesiated amides or deprotonated amines only 
produced mediocre yields of N-(n-Butyl)propionamidoxime 251a. The most promising 
result was obtained in this pilot study using lithium amides. We therefore undertook a 
side-by-side comparison of magnesiated (Method A) versus lithiated (Method B) amides 
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in the synthesis of amidoximes derived from various primary and secondary amines. 
Those data are summarized in Table 4.2. 
 
Table 4.2 Effect of Metallating Agent on the Synthesis of N-Alkylpropionamidoximes 
________________________________________________________________________ 
Amine    Yield w/ EtMgCl (%)  Yield w/ n-BuLi (%) 
  _____________________________Method A                               Method B_________ 
 n-Butylamine    28     59  
Cyclohexylamine   32     47  
tert-Butylamine   32     19  
Pyrrolidine    46     26 
________________________________________________________________________ 
 
 The amines in Table 4.2 were chosen to test the steric factors in different primary 
and secondary amines on the reactivity of the corresponding metallated amines. While 
the steric factors did not seem to affect the yields of the N-alkylpropionamidoximes when 
magnesiated amides were used, they significantly reduced the yields of the N-alkyl-
propionamidoximes when lithiated amides were used. The yields of amidoximes from 
tert-butylamine or pyrrolidine are half of those from n-butylamine or cyclohexylamine 
when n-butyllithium was the reagent. These results are perhaps not surprising because 
lithiated agents have more nucleophilic characteristic than magnesiated agents; thus, 
steric factors have more effects on lithiated agents. 
 When comparing between the two methods for each entry in Table 4.2, the data 
suggested that n-butyllithium was the preferred reagent for preparing N-(primary alkyl) 
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or N-(secondary alkyl) amidoximes. In the cases when n-butyllithium gave low yields of 
amidoximes, such as those from tert-butylamine or pyrrolidine, metallation using 
Grignard reagents might be an alternative solution. 
Having tested the effects of various metallating agents and of the amine structure, 
the amidoxime synthesis was further applied to several different nitroalkanes in order to 
expand its scope and generality. In so doing, the use of additional amine components, 
including unsaturated amines and anilines, was also explored. Figure 4.1 depicts the 
structures of various new amidoximes that were synthesized from nitromethane, 
nitroethane and 1-nitropropane. Each structure in the figure also indicates the optimal 
method of preparation, and the yield obtained. 
 Despite the strongly basic conditions involved, the method successfully afforded 
amidoximes, although in moderate yields. Attempts to prepare amidoxime 251i from 
allylamine were unsuccessful using Method B, probably because of polylithiation, which 
has been reported to be THF-catalyzed.
17,18
 However, by switching to Method A, 251i 
could be synthesized in low yield. 
 The most successful results were obtained using anilines, as indicated by the 
formation of amidoximes 251f and 251j. Besides being notable for its yield (68%), the 
successful preparation of 251j establishes that the method tolerates the presence of some 
reactive (trifluoromethyl, nitrile) functionality in the amine component. 
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Figure 4.1 Examples of Amidoximes Prepared from Nitroalkanes 
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In summary, we have investigated new routes to amidoximes from the reactions 
of amines with nitronates or thiohydroxymate esters. Both pathways did not afford viable 
access to amidoximes. During this investigation, we discovered the first example of an 
amidoxime-to-amidine transformation by nucleophilic addition of an amine and 
elimination of NH2OH. 
We have also investigated the effect of metallating agent and amine substitution 
pattern in the condensation of nitronate anions with amide anions to produce 
amidoximes, an important family of medicinally active compounds. Two generally useful 
sets of conditions were developed and applied to the preparation of a representative 
family of amidoximes. The results we reported establish a useful new dimension to the 
chemistry of primary nitroalkanes, which are already important building blocks in 
organic synthesis. 
 
4.3 Experimental Procedures 
General Procedures 
1
H NMR and 
13
C NMR spectra were taken on a Varian Mercury-300 or a Varian 
Inova-400 spectrometer using CDCl3 with 0.05% v/v TMS or DMSO-d6 as solvents, 
recorded in δ (ppm), and referenced to TMS (0.00 ppm for 1H NMR and 77.16 ppm for 
13
C NMR) or DMSO-d6 (2.50 ppm for 
1
H NMR and 39.52 ppm for 
13
C NMR). IR spectra 
were obtained using a Thermo Nicolet Avatar 370DTGS FT-IR spectrometer and 
recorded in wavenumbers (cm
-1
). Melting points were measured using a Thomas Hoover 
Uni-melt capillary melting point apparatus or a Mel-Temp apparatus. Mass spectra were 
measured at the Life Sciences Core Laboratories Center using ABI/MDS Sciex 4000 Q 
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Trap. Chemicals were obtained from Aldrich, Acros, Aensar, Fisher, or Matrix Scientific, 
and used as received unless otherwise specified. 
General Procedure for the Synthesis of Amidoximes Using Ethylmagnesium Chloride 
(Method A) 
 A solution of ethylmagnesium chloride (2 mL of 2 M solution in THF, 4 mmol) in 
dry THF (2 mL) in a nitrogen-flushed 2-neck 50 mL round-bottom flask fitted with a 
condenser and septum was brought to reflux, and the amine (4 mmol, freshly distilled 
over sodium hydride) was added neat dropwise. The resulting solution was stirred at 
reflux until the evolution of ethane gas was complete. The oil bath was lowered, and 
nitroalkane (1 mmol, freshly distilled over sodium hydride) was added dropwise. The 
septum was replaced with a glass stopper, and the resulting solution was brought to reflux 
for 3 h. The reaction solution was cooled to 0 ºC and acidified to pH 2 with 3 M aqueous 
HCl. The bulk of THF was removed in vacuo and the residual aqueous phase was washed 
with ethyl ether (4 x 5 mL), cooled to 0 ºC and then basified to pH 10 using 3 M NaOH. 
The resulting viscous suspension was saturated with sodium chloride and extracted with 
ethyl ether (4 x 10 mL; caution: emulsions may form). The combined ether layers were 
washed with brine, dried (MgSO4), filtered and concentrated in vacuo to afford the 
desired amidoxime. 
General Procedure for the Synthesis of Amidoximes Using n-Butyllithium (Method B)
 A solution of amine (4 mmol, freshly distilled over sodium hydride) in dry THF 
(1.5 mL) in a nitrogen-flushed 2-neck 50 mL round-bottom flask fitted with a condenser 
and septum was cooled to -78 ºC, then n-butyllithium (2.5 mL of 1.6 M solution in 
hexanes, 4 mmol) was added. After warming the reaction mixture to rt and then back to 0 
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ºC, nitroalkane (1 mmol, freshly distilled over sodium hydride) was added dropwise. The 
septum was replaced with a glass stopper, and the resulting suspension was brought to 
reflux for 3 h, (note: the stir bar was agitated to dislodge any solids sticking to the walls 
of the flask). The reaction suspension was cooled to 0 ºC and acidified to pH 2 with 3 M 
HCl. The bulk of THF was removed in vacuo and the residual aqueous phase was washed 
with ethyl ether (4 x 5 mL), cooled to 0 ºC and then basified to pH 10 using 3 M NaOH. 
The resulting mixture was saturated with sodium chloride and extracted with ethyl ether 
(4 x 10 mL). The combined ether layers were washed with brine, dried (MgSO4), filtered 
and concentrated in vacuo to afford the desired amidoxime. 
1
H NMR, 
13
C NMR, IR, and MS for Amidoxime Products 
 Amidoxime 251a: The product was obtained as an orange oil (85.5 mg, 59%). 
1
H 
NMR and IR matched with literature.
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1H NMR (400 MHz, CDCl3) δ 8.52 (br, 1H), 5.14 
(br s, 1H), 3.10 (m, 2H), 2.23 (q, 2H), 1.49 (m, 2H), 1.36 (m, 2H), 1.14 (t, 3H), 0.93 (t, 
3H). IR (neat) 3233 (br), 2959 (s), 2933 (s), 2873 (s), 1645 (s). 
Amidoxime 251b: The product was obtained as a yellow solid (45.9 mg, 32%). 
1
H 
NMR (400 MHz, CDCl3) δ 8.24 (br, 1H), 5.30 (br s, 1H), 2.40 (q, 2H), 1.33 (s, 9H), 1.16 
(t, 3H). 
13
C NMR (400 MHz, CDCl3) δ 156.24, 50.63, 31.53, 23.65, 10.99. IR (CH2Cl2) 
3241 (br), 2974(s), 2939 (m), 2877 (m), 1633 (s). ESI-MS (CH3OH) 144.9 (M+H), 167.2 
(M+Na), 183.2 (M+K). 
Amidoxime 251c: The product was obtained as an orange solid (80.7 mg, 47%). 
1
H NMR (400 MHz, CDCl3) δ 8.39 (br, 1H), 5.13 (br d, 1H), 3.13 (m, 1H), 2.24 (q, 2H), 
1.88 (m, 2H), 1.75 (m, 2H), 1.60 (m, 2H), 1.37-1.15 (m, 2H), 1.14 (t, 3H). 
13
C NMR (400 
MHz, CDCl3) δ 155.47, 50.57, 35.25, 25.43, 25.17, 22.23, 11.25. IR (CH2Cl2) 3207 (br), 
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2932(s), 2853 (s), 1641 (s). ESI-MS (CH3OH) 171.2 (M+H), 193.2 (M+Na), 209.2 
(M+K). 
Amidoxime 251d: The product was obtained as an orange solid (64.8 mg, 46%). 
1
H NMR (400 MHz, CDCl3) δ 8.89 (br, 1H), 3.26 (m, 4H), 2.53 (q, 2H), 1.86 (m, 4H), 
1.17 (t, 3H). 
13
C NMR (400 MHz, CDCl3) δ 160.83, 46.40, 25.02, 19.64, 10.73. IR 
(CH2Cl2) 3207 (br), 2967(s), 2874 (s), 1628 (s). ESI-MS (CH3OH) 143.04 (M+H), 
165.12 (M+Na), 181.20 (M+K). 
Amidoxime 251e: The crude product was obtained as a yellow oil, of which a 
portion was purified by silica gel flash column chromatography (ethyl acetate, Rf = 0.30) 
to afford a yellow oil (69.4 mg, calculated total yield 44%). 
1
H NMR (400 MHz, CDCl3) 
δ 9.47 (br, 1H), 7.43-7.04 (m, 5H), 5.62 (br s, 1H), 4.31 (d, 2H), 2.21 (q, 2H), 1.11 (t, 
3H). 
13
C NMR (400 MHz, CDCl3) δ 156.13, 139.43, 128.73, 127.34, 126.78, 45.89, 
22.09, 10.86. IR (neat) 3206 (br), 3085 (s), 3061 (s), 3028 (s), 2974 (s), 2935 (s), 2874 
(s), 1646 (s). ESI-MS (CH3OH) 179.1 (M+H). 
Amidoxime 251f : The product was purified by silica gel flash column 
chromatography (1:1 ethyl acetate:hexanes, Rf = 0.30) to afford a yellow solid (91.5 mg, 
56%). 
1
H NMR (400 MHz, CDCl3) δ 9.79 (br, 1H), 7.30 (m, 2H), 7.18-6.99 (m, 3H), 2.39 
(q, 2H), 1.02 (t, 3H). 
13
C NMR (400 MHz, CDCl3) δ 154.19, 139.01, 129.16, 124.64, 
124.20, 22.58, 10.80. IR (CH2Cl2) 3187 (br), 2978 (m), 2939 (m), 2877 (m), 1641 (s), 
1598 (s). ESI-MS (CH3OH) 165.04 (M+H). 
Amidoxime 251g: The product was obtained as a light yellow solid (47.4 mg, 
41%, m.p. 73-75 
o
C). 
1
H NMR and 
13
C NMR matched with literature.
16
 
1
H NMR (400 
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MHz, CDCl3) δ 9.29 (br, 1H), 6.85 (d, 1H), 5.17 (br d, 1H), 1.25 (s, 9H). 13C NMR (400 
MHz, CDCl3) δ 142.62, 49.98, 30.56. 
Amidoxime 251h: The product was obtained as an orange solid (50.7 mg, 40%). 
1
H NMR matched with literature.
20
 
1H NMR (400 MHz, CDCl3) δ 8.88 (br, 1H), 3.25 (m, 
4H), 2.06 (s, 3H), 1.86 (m, 4H). 
13
C NMR (400 MHz, CDCl3) δ 156.62, 46.69, 25.04, 
11.90. 
Amidoxime 251i: The product was obtained as a yellow solid (29.4 mg, 26%). 
1
H 
NMR (300 MHz, CDCl3) δ 9.59 (br, 1H), 5.86 (m, 1H), 5.42 (br s, 1H), 5.17 (m, 2H), 
3.75 (s, 2H), 1.85 (s, 3H). 
13
C NMR (300 MHz, CDCl3) δ 152.87, 135.77, 115.61, 44.75, 
14.66. IR (CH2Cl2) 3241 (br), 3081(m), 2928 (m), 2859 (m), 1651 (s). ESI-MS (CH3OH) 
115.12 (M+H). 
Amidoxime 251j: The crude product was obtained as a yellow solid, of which a 
portion was purified by trituration with CH2Cl2 (2 x 2 mL) to afford a yellow solid (142.7 
mg, calculated total yield 68%, mp. 160.5-162 
o
C). 
1
H NMR (300 MHz, DMSO-d6) δ 
9.85 (s, 1H), 9.12 (s, 1H), 8.16 (d, 1H), 7.91 (d, 1H), 7.78 (dd, 1H), 2.02 (s, 3H). 
13
C 
NMR (300 MHz, DMSO-d6) δ 151.29, 145.91, 135.99, 131.64 (q), 124.56, 120.93, 
119.76, 116.52, 114.52 (q), 13.90. IR (CHCl3) 3356 (s), 3320 (m), 3249 (m), 3105 (m), 
2228 (s), 1612 (s), 1544 (s). ESI-MS (CH3OH) 244.08 (M+H). 
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Figure 4.2 
1
H NMR Spectrum of Amidoxime 251a 
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Figure 4.3 
13
C NMR Spectrum of Amidoxime 251a 
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Figure 4.4 
1
H NMR Spectrum of Amidoxime 251b 
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Figure 4.5 
13
C NMR Spectrum of Amidoxime 251b 
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Figure 4.6 
1
H NMR Spectrum of Amidoxime 251c 
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Figure 4.7 
13
C NMR Spectrum of Amidoxime 251c 
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Figure 4.8 
1
H NMR Spectrum of Amidoxime 251d 
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Figure 4.9 
13
C NMR Spectrum of Amidoxime 251d 
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Figure 4.10 
1
H NMR Spectrum of Amidoxime 251f 
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Figure 4.11 
13
C NMR Spectrum of Amidoxime 251f 
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Figure 4.12 
1
H NMR Spectrum of Amidoxime 251g 
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Figure 4.13 
13
C NMR Spectrum of Amidoxime 251g 
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Figure 4.14 
1
H NMR Spectrum of Amidoxime 251h 
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Figure 4.15 
13
C NMR Spectrum of Amidoxime 251h 
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Figure 4.16 
1
H NMR Spectrum of Amidoxime 251i 
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Figure 4.17 
13
C NMR Spectrum of Amidoxime 251i 
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Figure 4.18 
1
H NMR Spectrum of Amidoxime 251j 
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Figure 4.19 
13
C NMR Spectrum of Amidoxime 251j 
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CHAPTER 5 
Studies on a thia-Ugi Reaction: A Catalytic Oxidation of Isonitriles to 
Isocyanates 
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5.1 Background 
 Since its discovery in 1959, the Ugi reaction has arguably been one of the most 
important multicomponent reactions (MCRs).
1,2
 By producing the biologically relevant α-
aminoacyl amide or dipeptide motif, the Ugi reaction is widely used in the synthesis of 
many drugs and bioactive compounds.
3,4
 
 As discussed earlier in Chapter 1, our laboratory has recently developed a variant 
of the Ugi reaction resulting in a 5-component condensation (Scheme 1.11).
5
 The process 
was based on an alternative synthetic approach to imine, from the condensation of 
organometallic reagents with nitriles and primary amines. 
 Guided by the single reactant replacement (SRR) approach, we wondered whether 
the imine species in the Ugi reaction could be replaced with a comparable electrophilic 
thionium ion species. Such replacement might lead to products involving new motifs like 
253 and 254 (Scheme 5.1).  
 
 
Scheme 5.1 
 
 Thionium ions, which have the general structure , are synthetically 
useful species and have been widely used in the preparation of α-substituted sulfides.6,7 
For example, Li et al. recently used thionium ions 258 and 261 as intermediates in their 
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synthesis of thiokifunensine 264 (Scheme 5.2), which is a thioanalog of the naturally-
occurring anti-HIV, anti-cancer, and immunomodulating agent kifunensine.
8
 A 
preliminary biological evaluation showed that 264 also exhibited good anti-HIV 
inhibitory activity. The thionium species 258 was generated by a Pummerer reaction 
between sulfoxide 257 and acetic acid or acetic anhydride at 100 °C, affording α-
substituted sulfide 259. A second Pummerer reaction was performed on sulfoxide 260 to 
form the corresponding unstable ketal 262, which converted to the protected 
thiokifunensine 263. Subsequent hydrolysis of 263 led to the formation of 
thiokifunensine 264.  
 
 
Scheme 5.2
8
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 Thionium ions can also be used as intermediates to make heteroaromatic rings. 
For example, Satoh and Miyagawa cleverly used thionium species 269 as an electrophilic 
intermediate for the attack of an internal ketone nucleophile to form the substituted furan 
270 in a two-step procedure (Scheme 5.3).
9
 Intermediate 269 was formed by the 
Pummerer reaction of the sulfoxide 267 with trifluoroacetic anhydride (TFAA).  
 
Scheme 5.3
9
 
 
Recently, Padwa et al. used thionium ions to promote Mannich cyclization 
reactions.
10,11
 For example, the isoquinolinone ring system 279 was formed from a 
thionium ion cyclization cascade (Scheme 5.4). The thionium ion 276 was generated 
from the reaction between thioacetal 273 and dimethyl(methylthio)sulfonium 
tetrafluoroborate (DMTSF) 274. This reaction provided an alternative method for 
thionium ions and was first discovered by Trost and Murayama in 1981.
12,13
 The 
electrophilic thionium ion in 276 was then attacked by the amido nitrogen atom to 
produce the phenylthio-substituted lactam 277, which then underwent elimination of 
thiophenol to afford N-acyliminium ion 278.
10,11
 Subsequent cyclization with the 
aromatic ring led to the isoquinolinone ring system 279. 
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Scheme 5.4
10,11
 
 
 
  
Scheme 5.5
11
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Currently, thionium ions may be prepared from several different precursors, as 
summarized in a recent report by Padwa and Waterson (Scheme 5.5).
11
 Of these routes, 
the most convenient source of a thionium ion comes from the Pummerer reaction, in 
which the corresponding sulfoxide 280 reacts with acetic anhydride 281 (Scheme 5.6). 
The normal product of the Pummerer reaction is the α-acyloxy-thioether 285. We hoped 
that by adding an isonitrile to the Pummerer reaction mixture, it would compete with the 
carboxylate ion 283 in attacking the electrophilic thionium ion intermediate 284, which 
would lead to the formation of the intermediate 286. Subsequent rearrangement of 286 
would lead to a structure like 287. However, if 286 instead underwent hydrolysis, a 
structure like 288 would arise.  
 
 
Scheme 5.6 
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5.2 Results and Discussion  
To begin this study, we chose di-n-butyl sulfoxide as a prototype and conducted 
the Pummerer reaction using acetic anhydride under typical conditions (neat Ac2O, 100 
°C, 5 h). Initially, the product after extractive workup was lost under high vacuum drying 
(0.3 mm Hg) overnight. Subsequently, the product after extractive workup was carefully 
concentrated under high vacuum (0.3 mm Hg, 30 min) to a constant weight. 
1
H NMR 
showed that the resulting orange oil was mixture of the expected Pummerer product 290 
(60%) and the elimination product butyl 1-butenyl sulfide 291 (40%) (Scheme 5.7). This 
result agreed with a previous report by Horner and Kaiser.
14
  
An aliquot of that mixture was then subjected to a reaction with excess neat tert-
butylisonitrile 292a at 80 °C for 2 days in an attempt to regenerate and intercept the 
desired thionium ion. However, a mixture of unidentifiable products was obtained after 
rotary evaporation (25 °C, 20 mm Hg). TLC of the resulting yellow oil showed multiple 
spots. 
1
H NMR spectrum showed broad and unresolved peaks. IR spectrum showed a 
weak amide carbonyl absorption. 
 
 
Scheme 5.7  
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 We next turned our attention to dibenzyl sulfoxide as an alternative test of the 
approach, for two reasons. First, the higher MW sulfoxide would form less volatile 
products, thus reducing the loss upon workup. Second, the Pummerer reaction of 
dibenzyl sulfoxide would not form elimination products like 291. 
 After dibenzyl sulfoxide 293 was stirred in neat acetic anhydride 281 at 100 °C 
for 5 hours, the reaction mixture was subjected to extractive workup. The expected 
product 294 (59%) and benzaldehyde dibenzyldithioacetal 295 (14%) were isolated after 
flash column chromatography (Scheme 5.8). Control experiments established that 295 
was derived from 294. In fact, the formation of thioacetals from sulfoxides under 
Pummerer-type conditions had been observed previously by Harris and Boekelheide, who 
proposed the mechanism of the self-condensation of α-dichloroacyloxy sulfide 296 
shown in Scheme 5.9.
15
 
 
 
Scheme 5.8 
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Scheme 5.9
15
 
 
 Interestingly, no reactions occurred when a purified sample of the normal 
Pummerer product 294 was subjected to a reaction with 1 equiv of tert-butylisonitrile at rt 
for 20 hours, and pure 294 was recovered in near-quantitative yield. A small amount of 
295 was also observed. An attempt to intercept the Pummerer reaction between dibenzyl 
sulfoxide 293 and acetic anhydride by including 3 equiv of tert-butylisonitrile in the 
reaction mixture was also unsuccessful, and led to unidentifiable products. 
 We reasoned that since the Pummerer reaction between sulfoxides and acetic 
anhydride required prolonged heating at high temperature, such conditions might favor 
by-product formation. The Pummerer reaction may be conducted at lower temperature 
using trifluoroacetic anhydride (TFAA). To our surprise, when dibenzyl sulfoxide was 
reacted with TFAA (1.3 equiv) and tert-butylisonitrile (1.3 equiv) in CH2Cl2 (0 °C → rt), 
dibenzyl sulfide 301 was obtained in near-quantitative yield (Scheme 5.10). This 
unexpected and efficient reduction of the sulfoxide was not observed in the comparable 
reaction of 293 with tert-butylisonitrile using acetic anhydride. 
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Scheme 5.10 
 
 From the mechanistic point of view, the reduction of sulfoxide 293 must be 
accompanied by an oxidation, most likely of tert-butylisonitrile. Real-time monitoring of 
the reaction mixture by IR unambiguously established the formation of isocyanate (strong 
band at 2257 cm
-1
). 
A literature search revealed that the Pummerer process could be intercepted using 
nucleophiles in different fashions as summarized in a recent report by Procter et al 
(Scheme 5.11).
7
 In the “classical” Pummerer reaction, sulfoxide 302 undergoes 
elimination upon O activation, leading to the formation of thionium ion 304. 
Nucleophiles such as acetate, arenes, alkenes, and phenols attack 304 to afford α-
substituted sulfide 305. Electrophiles used to activate sulfoxide 302 include acetic 
anhydride, TFAA, trifluoromethanesulfonic anhydride (Tf2O), or a silyl chloride. 
Nucleophiles used in the “classical” Pummerer reaction are usually unreactive towards 
these activators. Aromatic and vinyl sulfoxides would participate in “additive” and 
“vinylogous” reactions, respectively, to afford compounds such as 308, 311, and 312. 
Various nitrogen-containing nucleophiles, such as aromatic amines, carboxylic acid 
amides, and sulfonamides,
16
 would interrupt the Pummerer process at an earlier stage by 
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attacking the tricoordinate sulfur intermediate 303 at the sulfur atom, affording 
unexpected products like 313 and 314. 
 
 
Scheme 5.11
7
   
  
 Based on those findings, a plausible mechanism for the formation of isocyanate is 
depicted in Scheme 5.12. Nucleophilic attack of the oxy-sulfonium species 316 by tert-
butylisonitrile 292a afforded the nitrium species 318 which then fragmented, leading to 
the isocyanate 321a. 
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Scheme 5.12 
 
 Isocyanates, which embody the N=C=O functional group, undergo several 
synthetically useful reactions, including nucleophilic addition of alcohols and amines to 
produce urethanes and ureas, respectively.
17
 Isocyanates are also intermediates in several 
well-known organic reactions, including the Hofmann rearrangement of primary 
amides,
18
 the Curtius rearrangement of acyl azides,
19,20
 the Schmidt reaction of 
carboxylic acids with hydrazoic acid,
21
 and the Lossen rearrangement of hydroxamic 
acids.
22,23
 Diisocyanates are widely used in chemical industry to produce polyurethanes 
and other polymers.
24,25
  
 Given the broad synthetic utility of isocyanates, dozens of procedures have been 
described for preparing them, including several routes from isonitriles. Isonitrile-to-
isocyanate oxidations have been reported with the use of mercuric oxide,
26
 lead 
tetraacetate,
27
 and ozone,
28
 as well as halogen- or acid-catalyzed oxidations by 
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DMSO
29,30
 and pyridine N-oxide.
31
 However, recent interest in highly functionalized 
isocyanates drives the continuing demand for new synthetic methodology.
32,33
 
The proposed mechanism suggested that dimethyl sulfoxide (DMSO) might 
replace dibenzyl sulfoxide as a more convenient oxidizing agent. The mechanism also 
suggested that only a catalytic quantity of TFAA might be needed for the oxidation. To 
test these predictions, a sample of tert-butylisonitrile was treated with DMSO (1.1 equiv) 
and TFAA(0.05 equiv) at low temperature (CH2Cl2, - 78 °C to rt, 10 min), whereupon a 
strong isocyanate band was observed in the IR and trapping with tert-butylamine afforded 
di(tert-butyl)urea in 96% yield.  
TFAA-catalyzed oxidations of representative isonitriles 292a – f by DMSO are 
summarized in Table 5.1, and illustrate the broad scope and efficiency of the method. The 
data indicated that alkyl, cycloalkyl, and aryl isonitriles were smoothly transformed into 
isocyanates by using catalytic amounts of TFAA, with one exception. Oxidations of 
morpholinoethylisonitrile 292d with 5 – 20 % TFAA returned substantial amounts of the 
starting isonitrile. To test whether the morpholinyl group interfered with the catalysis, the 
oxidation of morpholinoethylisonitrile 292d was conducted with 1.1 equiv of TFAA. 
While the isonitrile was completely consumed, no characteristic stretching frequency for 
the isocyanate group in 321d was detected. Nevertheless, addition of tert-butylamine to 
the crude product afforded the expected urea 322d. This suggested that there were some 
other species that suppressed the signal of the isocyanate in the IR measurement. We 
were not sure about the structure of this new compound; it could be the adduct of the 
morpholinyl group and isocyanate. However, this new compound behaved just like an 
isocyanate because it reacted with tert-butylamine to afford the expected urea 322d.  
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Table 5.1 Oxidation of Isonitriles to Isocyanates 
________________________________________________________________________ 
 
a
 Spectroscopic data for all derivatives matched literature values.  
b
 1.1 equiv of TFAA was used in this experiment. 
________________________________________________________________________ 
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 Since the only byproducts accompanying isocyanate formation, dimethyl sulfide 
and residual TFAA, are volatile, it was of interest to determine whether some isocyanates 
might be isolated directly in nearly pure form by careful evaporative workup. Entries 5 
and 6 in Table 5.1 showed that cyclohexyl isocyanate 321e and ethyl isocyanatoacetate 
321f could be isolated in excellent yield by rotary evaporation of solvent and 
concentrated in vacuo to a constant weight. In each case, the only byproduct detectable 
by NMR was a few percent of residual DMSO. 
 The method reported here for catalytic oxidation of isonitriles to isocyanates is 
rapid and mild, and promises to be of utility to synthetic chemists. Besides using 
inexpensive, readily available reagents, the method generates volatile and innocuous 
byproducts, often making possible direct isolation of the desired isocyanates without 
extractive workup. 
 Unlike the halogen-catalyzed DMSO oxidations reported earlier,
29
 which require 
prolonged heating at reflux and have been proposed to involve isonitrile – halogen 
adducts, the TFAA-catalyzed oxidations that we developed occur rapidly at low 
temperature by a different mechanism. Our method is simple and easy to use, and 
represents a very mild, rapid, and environmentally acceptable procedure for preparing 
isocyanates from isonitriles. Not to be overlooked is the concomitant and equally useful 
synthetic conversion of sulfoxides to sulfides. 
 As a demonstration on the simplicity and usefulness of the method, ethyl 2-
isocyanatoacetate 321f was successfully synthesized from ethyl 2-isocyanoacetate 292f 
on a 7g scale in 96% yield (Scheme 5.13). 
 
173 
 
 
Scheme 5.13 
 
 Ethyl 2-isocyanatoacetate 321f has previously been prepared by the reaction of 
ethanol with 2-isocyanatoacetyl chloride.
34
 It has also been synthesized by the reaction of 
ethyl hydrogen malonate using diphenylphosphoryl azide via a Curtius rearrangement.
35
 
Ethyl 2-isocyanatoacetate can also be prepared from various glycine derivatives, 
including the reaction of N-tosylglycine ethyl ester
36
 or N-trimethylsilylglycine ethyl 
ester
37
 with phosgene, or the reaction of glycine ethyl ester hydrochloride with 
bis(trichloromethyl)carbonate.
38
 
 
5.3 Future Directions 
 Guided by the SRR approach, an attempt to replace the imine species in the Ugi 
reaction with a comparable electrophilic thionium ion species instead uncovered a fast 
and gentle catalytic oxidation of isonitriles to isocyanates. The formation of isocyanates 
instead of the desired “thia-Ugi” process may be understood if the tricoordinate sulfur 
intermediate 303 is intercepted by the isonitrile before it is converted into thionium ion 
304. Thus, Pummerer reaction was not a fruitful source of thionium ions in our study. To 
solve this problem, we need to access thionium ions from an alternative route. 
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Scheme 5.14 
  
Of all the routes to thionium ions from different precursors shown in Scheme 5.5, 
the approach from thioketals and DMTSF does not go through a tricoordinate sulfur 
intermediate, thus it might prevent the problem observed in the Pummerer reaction of 
sulfoxides (Scheme 5.14). 
 
5.4 Experimental Procedures 
General Procedures 
1
H NMR spectra were taken on a Varian Inova-400 spectrometer using CDCl3 
with 0.05% v/v TMS or DMSO-d6 as solvents, recorded in δ (ppm), and referenced to 
TMS (0.00 ppm) or DMSO-d6 (2.50 ppm). 
13
C NMR spectra were taken on a Varian 
Inova-400 spectrometer using CDCl3 with 0.05% v/v TMS as solvent, recorded in δ 
(ppm), and referenced to CDCl3 (77.16 ppm for 
13
C NMR). IR spectra were obtained 
using a Thermo Nicolet Avatar 370DTGS FT-IR spectrometer and recorded in 
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wavenumbers (cm
-1
). Melting points were measured using a Thomas Hoover Uni-melt 
capillary melting point apparatus. Mass spectra were measured at the Life Sciences Core 
Laboratories Center using ABI/MDS Sciex 4000 Q Trap. Chemicals were obtained from 
Aldrich, Acros, Aensar, or Fluka and used as received unless specified. 
Reduction of Dibenzyl Sulfoxide 293 to Dibenzyl Sulfide 301 
Dibenzyl sulfoxide (115 mg, 0.5 mmol, recrystallized from ethanol) was 
dissolved in dry CH2Cl2 (0.5 mL) under N2 in a 25 mL round-bottom flask. tert-Butyl 
isonitrile (74 µL, 0.65 mmol) was added via syringe. After cooling the solution to 0 °C, 
TFAA (91µL, 0.65 mmol) was added dropwise.  The resulting solution was stirred 
vigorously at 0 
o
C for 5 min, then warmed to rt and stirred for 5 min. The solution was 
then concentrated in vacuo to afford a white paste, which was then purified by flash 
column chromatography (1:15 ethyl acetate:hexane, Rf=0.35) to afford the desired sulfide 
301 as a white solid (94 mg). Yield: 88%. 
Representative Procedure for the Catalytic Oxidation of Isonitriles to Isocyanates: 
Oxidation of tert-Butyl Isonitrile 292a and Trapping with tert-Butylamine to Afford 
di(tert-Butyl)urea 322a  
A solution of tert-butylisonitrile (113 µL, 1 mmol) in dry CH2Cl2 (1 mL) and dry 
DMSO (78 µL, 1.1 mmol) under N2 in a 25 mL round-bottom flask was cooled to -60 
o
C, 
then TFAA (7 µL, 0.05 mmol) was added.  The resulting solution was stirred vigorously 
at -60 
o
C for 5 min, then warmed to rt and stirred for 5 min. After cooling the solution 
again to -60 
o
C, t-butylamine (315 µL, 3 mmol) was added dropwise. The resulting 
solution was stirred at rt for 2 hr, then concentrated in vacuo to afford a white solid.  
Water (3 mL) was added and the aqueous phase was extracted with ethyl acetate (4 x 5 
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mL). The combined organic extracts were washed with brine (2 mL), dried (MgSO4), 
filtered, and concentrated in vacuo to afford di(tert-butyl)urea 322a as a white solid (165 
mg). Yield: 96%, m.p. 252 – 254 oC (sealed capillary tube) (lit.39 240 oC). 
N-n-butyl-N'-tert-butylurea 322b: Yield: 95%, m.p. 73–76 oC (lit.40 71–72 oC). 
N-tert-butyl-N’-4-methoxyphenylurea 322c: Yield: 61%, m.p. = 129 – 130. 5 oC 
(lit.
41
 128 – 130 oC). 
N-tert-butyl-N’-2-morpholinoethylurea 322d: Yield: 67%. IR (neat) 3350(s), 
2961(s), 2926(m), 2856(m), 2811(m), 1638(s), 1558(s). ESI-MS (CH3OH) 230 (M+H). 
Representative Procedure for the Catalytic Oxidation of Isonitriles with Direct 
Isolation of the Isocyanate: Ethyl 2-Isocyanatoacetate 321f 
A solution of ethyl 2-isocyanoacetate (115 µL, 1 mmol) in dry CH2Cl2 (1 mL) and 
dry DMSO (78 µL, 1.1 mmol) under N2 in a 25 mL round-bottom flask was cooled to -60 
o
C, then TFAA (7 µL, 0.05 mmol) was added.  The resulting solution was stirred 
vigorously at -60 
o
C for 5 min, then warmed to rt and stirred for 5 min. The solution was 
then concentrated using a rotary evaporator and then in vacuo (0.2 Torr) for 1 min to 
afford the desired isocyanate 321f as brown oil (122 mg). Yield: 95%. IR and 
1
H NMR 
matched with those in the Aldrich Spectral Library. IR (neat) 3349(m), 2986(m), 2254(s), 
1747(s). 
Cyclohexyl isocyanate 321e: Yield: 94%. IR and 
1
H NMR matched those in the 
Aldrich Spectral Library. IR (neat) 2937(s), 2858(m), 2263(s). 
Procedure for the Synthesis of Ethyl 2-Isocyanatoacetate 321f on a 7g Scale 
Caution: Dimethyl sulfide, a by-product of this reaction, is a highly flammable 
liquid and an irritant with an extremely unpleasant odor. The experimentalist should 
177 
 
wear gloves, and the reaction and its workup should always be performed in a well-
ventilated hood.  
A 250-mL round-bottomed flask with a 24/40 joint equipped a Teflon-coated 
oval-shaped magnetic stir bar (3.2 cm x 1.5 cm) and topped with a rubber septum is 
flushed with nitrogen (Note 1). Dichloromethane (60 mL) is added via syringe (Note 2). 
Ethyl 2-isocyanoacetate (7.0 mL, 60.8 mmol) is added via syringe to afford a brown 
solution (Note 3). Dimethyl sulfoxide (5.4 mL, 76 mmol) is added via syringe (Note 4). 
The resulting solution is cooled to –78 °C in a dry ice/acetone bath, then trifluoroacetic 
anhydride (0.86 mL, 6.2 mmol) is added dropwise via syringe over 5 min (Note 5). The 
resulting solution is stirred for 5 min at –78 °C, then the dry ice/acetone bath is removed, 
and the dark brown solution is allowed to warm to rt over 1 h and stirred for an additional 
5 min (Note 6). The magnetic stir bar is removed using a Teflon-coated magnet retriever 
and rinsed with dichloromethane (0.5 mL). The reaction mixture is concentrated in the 
hood by rotary evaporation at 20 mm Hg. The resulting brown concentrate is dissolved in 
ice-cold dichloromethane (20 mL) and washed with three 10 mL portions of ice-cold 
deionized water. The organic layer is dried over anhydrous magnesium sulfate powder 
(1g) and filtered through a 30 mL sintered glass funnel using 3 x 5 mL portions of fresh 
solvent for rinsing (Note 7). The filtrate is concentrated by rotary evaporation (25 °C, 20 
mm Hg) (Note 8) and then under high vacuum (0.3 mm Hg) for 30 min to afford 7.58–
7.66 g (96–97%) of 321f as a dark brown oil (Notes 9 and 10). 
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Note: 
 1. The round-bottomed flask and the magnetic stir bar were dried in an oven, 
cooled to room temperature under high vacuum, and subsequently maintained under a 
positive pressure of nitrogen.  
2. Dichloromethane (Optima® grade) was purchased from Fisher Scientific and 
dried over activated alumina solvent purification system (Innovative Technology Inc. 
Pure Solv™).  
3. Ethyl 2-isocyanoacetate (95%) was purchased from Aldrich Chemical 
Company Inc. and the dark brown oil was used without further purification.  
4. Dimethyl sulfoxide (DMSO, anhydrous, ≥99.9%) was purchased from Sigma-
Aldrich and used without further purification.  
5. Trifluoroacetic anhydride (≥99%) was purchased from Sigma-Aldrich and used 
without further purification.  
6. After stirring at room temperature for 5 min, a few drops of the reaction 
solution were removed via Pasteur pipet and submitted to IR analysis to confirm that the 
reaction was complete (complete disappearance of isonitrile stretch at 2164 cm
-1
; 
appearance of isocyanate stretch at 2255 cm
-1
).  
7. Magnesium sulfate anhydrous powder was purchased from Fisher Scientific 
and used without further purification.  
8. Removing the bulk of the solvent by rotary evaporation was judged complete 
when the flask no longer felt cold to the touch after the water bath was lowered from the 
evaporator.  
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9. The product was a dark brown oil which appeared pure by 
1
H and 
13
C NMR 
spectroscopy. When stored at room temperature, the neat product decomposed with a 
half-life of ca. 12 h into unidentifiable solid. However, decomposition could be 
suppressed by wrapping the sample in aluminum foil and storing it neat at –10 °C. After 
4 days, only traces of solid decomposition product were observed.  
10. The product isocyanate displayed the following spectroscopic characteristics, 
which matched published spectra:
37,42
 
1
H NMR (500 MHz, CDCl3) δ: 1.32 (t, 3 H, J = 7.2 
Hz), 3.94 (s, 2 H), 4.29 (q, 2 H, J = 7.2 Hz); 
13
C NMR (125 MHz, CDCl3) δ: 13.9, 44.4, 
62.4, 127.3 (weak), 169.2; IR (neat, cm
-1
): 3363 (m), 2987 (m), 2943 (m), 2255 (s), 1749 
(s). 
 
180 
 
 
Figure 5.1 
1
H NMR Spectrum of Dibenzyl Sulfide 301 
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Figure 5.2 
1
H NMR Spectrum of di(tert-Butyl)urea 322a 
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Figure 5.3 
1
H NMR Spectrum of N-n-Butyl-N'-tert-Butylurea 322b 
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Figure 5.4 
1
H NMR Spectrum of N-tert-Butyl-N’-4-Methoxyphenylurea 322c 
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Figure 5.5 
13
C NMR Spectrum of N-tert-Butyl-N’-4-Methoxyphenylurea 322c 
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Figure 5.6 
1
H NMR Spectrum of N-tert-Butyl-N’-2-Morpholinoethylurea 322d 
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Figure 5.7 
13
C NMR Spectrum of N-tert-Butyl-N’-2-Morpholinoethylurea 322d 
187 
 
 
Figure 5.8 
1
H NMR Spectrum of Cyclohexyl Isocyanate 321e 
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Figure 5.9 
13
C NMR Spectrum of Cyclohexyl Isocyanate 321e 
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Figure 5.10 
1
H NMR Spectrum of Ethyl 2-Isocyanatoacetate 321f 
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Figure 5.11 
13
C NMR Spectrum of Ethyl 2-Isocyanatoacetate 321f 
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